Peptide-based platform enabling amphiphilic block copolymers to acquire in vitro transfection ability and more potent in vivo lung gene transfer for cystic fibrosis by Guan, Shan
 Aus der Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen 
Kinderspital der Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. med. Dr. sci. nat. Christoph Klein 
 
 
 
 
Peptide-based platform enabling amphiphilic 
block copolymers to acquire in vitro 
transfection ability and more potent in vivo 
lung gene transfer for cystic fibrosis 
 
 
Dissertation zur Erlangung des Doktorgrades der 
Naturwissenschaften an der Medizinischen Fakultät  
der Ludwig-Maximilians-Universität München 
 
 
vorgelegt von 
 
Shan Guan 
 
aus Huopu, China 
 
 
2017 
 Gedruckt mit Genehmigung der Medizinischen Fakultät der Ludwig-
Maximilians-Universität München  
 
 
 
 
 
 
 
 
Betreuer: PD. Dr. Carsten Rudolph 
 
 
 
Zweitgutachter: Prof. Dr. Alexander Dietrich  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dekan: Prof. Dr. med. dent. Reinhard Hickel 
 
 
 
Tag der mündlichen Prüfung: 06. 03. 2018 
 
  
 
 
 
 
 
 
 
 
“We will hew out of the mountain of despair a stone of hope.” 
Martin Luther King Jr., 1963 
 
Table of Contents 
I 
 
TABLE OF CONTENTS 
 
1 INTRODUCTION ................................................................................................................. 1 
1.1 Gene therapy for cystic fibrosis ................................................................................... 1 
1.2 Clinical trials of CF gene therapy ................................................................................ 5 
1.2.1 Clinical trials of CF gene therapy using viral vectors ....................................... 6 
1.2.2 Clinical trials of CF gene therapy using nonviral vectors ................................. 9 
1.3 Potential next generation nonviral delivery systems for CF gene therapy ................. 12 
1.4 Aims of the thesis ....................................................................................................... 15 
2 MATERIALS AND METHODS .......................................................................................... 19 
2.1 Materials ..................................................................................................................... 19 
2.1.1 Reagents .......................................................................................................... 19 
2.1.2 Nucleic acids ................................................................................................... 20 
2.2 Methods ...................................................................................................................... 20 
2.2.1 Synthesis of peptides ....................................................................................... 20 
2.2.2 Cell culture ...................................................................................................... 21 
2.2.3 Preparation of mRNA/pDNA based binary and ternary complexes ............... 21 
2.2.4 Size and zeta potential measurements ............................................................. 22 
2.2.5 Transmission electron microscopy .................................................................. 23 
2.2.6 Agarose gel retardation assay .......................................................................... 23 
2.2.7 In vitro transfection ......................................................................................... 24 
2.2.8 Nebulization study ........................................................................................... 25 
2.2.9 Flow cytometry ............................................................................................... 25 
2.2.10 Confocal microscopy ..................................................................................... 27 
Table of Contents 
II 
2.2.11 Cytotoxicity assay ......................................................................................... 28 
2.2.12 Animal studies ............................................................................................... 28 
2.2.13 Histology ....................................................................................................... 30 
2.2.14 Immunohistochemical analysis ..................................................................... 30 
2.2.15 Statistics ........................................................................................................ 31 
3 RESULTS ............................................................................................................................. 32 
3.1 Establishing poloxamine 704 (T704)-peptide ternary complexes .............................. 32 
3.1.1 T704 based binary complexes were invalid for in vitro transfection .............. 32 
3.1.2 Investigations on parameters influencing in vitro transfection efficiency of 
ternary complex ........................................................................................................ 34 
3.2 Characterization of ternary complexes and binary counterparts ................................ 39 
3.2.1 Agarose gel retardation assay .......................................................................... 39 
3.2.2 Dynamic light scattering (DLS) measurements .............................................. 42 
3.2.3 Transmission electron microscopy (TEM) ...................................................... 43 
3.2.4 Stability of ternary complexes ......................................................................... 44 
3.3 Investigations on the underlying mechanism of the superior transfection efficiency of 
ternary complex compared with the binary counterpart ................................................... 47 
3.3.1 Cellular internalization of binary and ternary complexes ............................... 47 
3.3.2 Cellular internalization pathways of ternary complex .................................... 48 
3.3.3 Subcellular localization of binary and ternary complexes .............................. 52 
3.4 Optimizing peptide structure with different candidate modules ................................ 53 
3.4.1 Each moiety that constitutes the peptide is imperative for the activity of 
peptide in ternary complex ....................................................................................... 53 
3.4.2 Optimizing the peptide structure with different candidate modules ............... 55 
3.5 Comparisons between the ternary complexes and other nonviral transfection reagents
 .......................................................................................................................................... 62 
Table of Contents 
III 
3.5.1 In vitro luciferase expression mediated by different carrier systems .............. 62 
3.5.2 In vitro enhanced green fluorescent protein (EGFP) expression mediated by 
different carrier systems ........................................................................................... 64 
3.6 Cytotoxicity ................................................................................................................ 68 
3.6.1 Cytotoxicity of formulations based on ternary complexes, Lipofectamine2000 
lipoplex and brPEI polyplex in the optimum composition....................................... 68 
3.6.2 Cytotoxicity of T704, peptide 9, Lipofectamine2000 and brPEI .................... 69 
3.7 In vivo evaluation of ternary complexes .................................................................... 70 
3.7.1 In vivo mRNA expression mediated by ternary complex ............................... 70 
3.7.2 In vivo evaluation of pDNA transfection efficiency mediated by ternary 
complex .................................................................................................................... 72 
3.7.3 In vivo toxicity of ternary complex ................................................................. 74 
3.8 In vivo long-term transgene expression mediated by ternary complexes containing 
SleepingBeauty (SB) transposon system .......................................................................... 77 
3.8.1 In vivo long-term luciferase expression .......................................................... 77 
3.8.2 In vivo long-term CFTR expression ................................................................ 78 
3.9 Preliminary evaluation of ternary complexes comprising other poloxamines or 
poloxamers ....................................................................................................................... 80 
3.9.1 In vitro evaluation of ternary complexes consisting of T304 .......................... 80 
3.9.2 In vitro evaluation of T904 based ternary complexes ..................................... 83 
3.9.3 In vitro evaluation of ternary complexes consisting of T90R4 ....................... 86 
3.9.4 In vitro evaluation of ternary complexes consisting of L64 ............................ 90 
4 DISCUSSION ...................................................................................................................... 94 
4.1 Establishing and characterization of ternary complexes ............................................ 95 
4.2 Investigations of the underlying mechanism of the superior transfection efficiency of 
ternary complex compared with the binary counterpart ................................................... 96 
Table of Contents 
IV 
4.3 Optimizing peptide structure with different candidate modules ................................ 97 
4.4 Comparison of the transfection efficiency of ternary complexes with other nonviral 
transfection reagents ......................................................................................................... 99 
4.5 Cytotoxicity .............................................................................................................. 100 
4.6 In vivo long-term restoration of CFTR deficiency ................................................... 101 
4.7 Distinct behaviors of ternary complexes comprising different poloxamines ........... 105 
5 SUMMARY ........................................................................................................................ 107 
5 ZUSAMMENFASSUNG .................................................................................................... 109 
6 APPENDIX ......................................................................................................................... 111 
6.1 Abbreviations ........................................................................................................... 111 
6.2 Supporting figures and tables ................................................................................... 115 
7 REFERENCE ...................................................................................................................... 121 
8 PUBLICATION .................................................................................................................. 132 
9 ACKNOWLEDGEMENTS ................................................................................................ 133 
AFFIDAVIT ........................................................................................................................... 135 
 
 
Introduction 
1 
1 INTRODUCTION  
1.1 Gene therapy for cystic fibrosis 
Gene therapy is a potent therapeutic approach for many hereditary disorders in the lung which 
are intractable to current treatments. Among these genetic diseases, cystic fibrosis (CF) is the 
subject at the front line of numerous preclinical studies and human clinical trials. CF is a 
hereditary disease mainly occurred within Caucasian populations. Although CF is a rare 
disease with an incidence of one per 2,700-3,600 newborns
1
, there are still more than 80,000 
people in the European Union and the United States suffering from this disease. CF influences 
many organs of the CF patient, including the lung, the liver, the gastrointestinal tract and so 
on, with the airways most severely influenced
2
. Different organs also display different clinical 
symptoms from non-typical one to classical presentations
3
. The most common clinical 
symptom of CF patients is that their airways are severely influenced by bacterial infection as 
well as neutrophilic inflammation resulted from the thickened mucus covered on the airway 
epithelia
4
. The majority of CF patients die from the deteriorated lung diseases. The lifespan of 
CF patients could currently reach to around 40 years because of the developed medical care 
conditions and some small molecular drugs. Nevertheless, there are still no remedies which 
target to correct the origin of the disease, and the CF patients still suffer from a heavy burden 
of medication
5
. 
 
CF was first recorded as a disease entity in 1938, whereas the underlying mechanism of this 
disease at the genetic level was revealed until 1989 when scientists found that CF is caused by 
the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)  gene
6–8
. 
The CFTR gene is composed of 27 exons and contains a region of 190 kb
7
. CFTR gene 
encodes for a protein (CFTR protein) which consists of ~1500 amino acids with many 
functional domains within
9
. The CFTR protein should be localized to the apical membrane of 
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the epithelium of many organs (e.g., the airway, the sweat gland and the gastrointestinal tract) 
to exert their functions
10
.  
 
The CFTR protein plays a pivotal role in the regulation of cyclic adenosine monophosphate 
(cAMP) activated bicarbonate/chloride (Cl
-
) transport and sodium channels within the 
epithelium (Figure 1.1-1a)
11
. When the CFTR protein is dysfunctional, decreased mucociliary 
clearance and increased transepithelial water absorption would happen due to the abnormal 
transepithelial sodium absorption and decreased transepithelial Cl
-
 secretion (Figure 1.1-
1b)
12–14
. At the same time, the reduced bicarbonate secretion due to the dysfunctional CFTR 
may down-regulate the airway surface pH, which subsequently abolishes the innate bacterial 
defense mechanism and destroys the antibacterial activity of the airways (Figure 1.1-1b)
15,16
. 
The decreased antibacterial activity may initiate the deteriorated clinical symptoms in which a 
sterile newborn finally becomes a bacteria colonized condition
5
. Apart from that, many 
studies suggest that the CFTR protein is also expressed in some inflammatory cells including 
T cells, neutrophils and macrophages, indicating that the CFTR protein may have essential 
functions in the process of adaptive immune responses
17–21
. Though it is still in controversy, 
this hypothesis would be helpful in explaining the deteriorated inflammatory responses in the 
airway of CF patients
22
. 
 
a b  
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Figure 1.1-1 Schematic illustration of the CFTR functions in the case of the normal airway (a) and the 
case of CF airway induced by dysfunctional CFTR (b). CFTR regulates the transport of chloride (Cl
-
) and 
bicarbonate (HCO3
-
) across the epithelial cells. The normal airway is protected from exogenous bacteria and 
substances via endogenous antimicrobial mechanism and mucociliary transport that removes the foreign 
materials (a). The dysfunctional CFTR induces a decreased pH of airway surface liquid and the subsequent 
inhibition of bacterial killing abilities (b). The malfunction of CFTR protein within submucosal glands also 
influences the properties of mucus which is incapable of fulfilling the mucociliary clearance ability (b). 
 
The accurate presence of functional CFTR involves a set of cellular processes which should 
be occurred in a coordinated way. These processes include 1) the translation of primary CFTR 
transcript and its subsequent splicing; 2) the secretory process of CFTR protein; 3) 
localization of CFTR protein in the apical membrane of certain cells
10
. There are over 2000 
kinds of mutations within the CFTR gene being revealed up to date, but not all of them are 
disease causing
1
. Based on the resulting cellular phenotype, these mutations have been 
classified into six classes
2
. CFTR expression is completely abolished within class I to III 
mutations while residual CFTR function could be found within classes IV to VI mutations. As 
a result, class I to III mutations are severe mutations and classes IV to VI mutations belong to 
mild mutations (Table 1.1)
2
. In class I mutations, transcribed messenger RNA is degraded by 
premature stop codons, thus the transcription process of CFTR gene is interrupted. Regarding 
class II mutations, CFTR protein is excluded from reaching the apical membrane due to 
premature degradation induced by endoplasmic reticulum (ER) retention
23
. The most 
frequently occurred CF phenotype causing mutation termed Phe508del, which can be detected 
in above 90% of CF patients worldwide and is associated with severe clinical symptoms, 
belongs to class II mutations
24
. Phe508del is caused by the deletion of 3 nucleotides encoding 
phenylalanine within the CFTR protein
6,25
. Such abnormal CFTR protein is misfolded and 
subsequently degraded due to the ER retention. For class III mutations, translated CFTR 
protein could reach the apical membrane but displays impaired channel function. The 
decreased flow rate of Cl
-
 and channel conductance could always be observed in class IV 
mutants due to the wrong location of CFTR protein within the channel conducting pore. Class 
V mutations could result in partial abnormal transcripts, and the amount of CFTR proteins 
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within this class of mutations could be varied from patient to patient
26,27
. Class VI mutations 
always result in the production of CFTR protein with reduced surface retention ability. One 
reasonable approach for CF treatment is to correct the abnormal CFTR proteins that produced 
in a specific class of mutations. For example, some aminoglycoside antibiotics and synthetic 
small molecular drugs could camouflage the premature termination codons within class I 
mutations and subsequently suppress the translational fidelity to produce full-length CFTR 
transcript
28,29,30
. For the treatment of class II mutations, some potent pharmacological 
chaperones are employed to bind with dysfunctional CFTR proteins in order to increase their 
stability
31
. The resulting complex is able to escape from ER retention and correctly localizes 
to the apical membrane
32
. Some CFTR activators (also termed as CF potentiators) have shown 
their promising in the correction of the channel defects within class III mutations
33
. The most 
successful CFTR activator is ivacaftor (developed by Vertex Pharmaceuticals with the 
trademark of Kalydeco
®
) which has been approved by FDA
34
. In clinical studies, the 
administration of ivacaftor led to improvement in pulmonary function and to lower levels of 
sweat chloride concentrations. Ivacaftor showed efficiency in clinical studies lasting from 24 
to 96 weeks in subjects with the forced expiratory volume in the first second greater than 40% 
of the expected value
35
. Fewer hospital stays, pulmonary exacerbations and antibiotic use 
were also observed. However, this revolutionary drug faces one serious drawback, since 
ivacaftor is only effective in a small group of CF patients carrying G551D  mutation in the 
class III CF mutations, which affects less than 5% of patients with CF
35,36
. Another FDA-
approved CFTR “potentiators” is Lumacaftor/ivacaftor (Orkambi®). Lumacaftor is a CFTR 
corrector which is able to aid in the maturation of CFTR protein and its trafficking to the cell 
surface within patients who hold the Phe508del mutation
37
. However, the efficacy of 
Orkambi
®
 appears much lower than the one of the Kalydeco
®
, which significantly limits the 
wide applications of Orkambi
®38
. The treatment of class IV to class VI mutations is normally 
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fulfilled by the utilization of “class II pharmacological chaperones” and “class III CFTR 
activators” to increase the total amount of CFTR protein localized to the apical membrane10. 
 
Table 1.1 Classifications of mutant CFTR gene  
 
 
Nevertheless, there are still many CF mutations that could not be classified because the 
mechanism of these mutations is not revealed yet
2
. Moreover, CF patients who share the 
identical class of mutations may show different responses after receiving the same type of 
therapeutic compound. Bisaminomethylbithiazole would be a prominent example for such 
case in which this remedy is valid for the treatment of Phe508del in class II mutants but is 
invalid for another class II mutation named P574H
31
. Therefore, therapeutic approaches 
aiming to target specific mutations are not ideal in the practical applications where more 
complicated CFTR genotypes occur. Different from the established small molecule drugs that 
are only valid for one specific mutation, there are no limitations in the approaches of utilizing 
gene therapy which aims to correct the dysfunctional CFTR at the genetic level. All types of 
classified and unclassified CF mutations could be beneficial from the same kind of gene 
therapy, without the need to determine what types of mutations the patients hold. Moreover, 
gene therapy could prevent pulmonary diseases at the very early stage. 
 
1.2 CF gene therapy in clinical trials  
Gene therapy for CF was enabled by the discovery of the CFTR gene in 1989
6–8
. The 
successful utilization of gene therapy in the case of other monogenic disorders significantly 
inspired the application of gene therapy for CF. The most common strategy of CF gene 
Mutation class Underlying reason example  
I Abnormal protein translation G542X 
II Abnormal  protein processing Phe508del 
III Abnormal  channel regulation G551D 
IV Abnormal  protein conductance R117H 
V Decreased protein production A455E 
VI Decreased  protein surface rentention c.120del23 
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therapy is to deliver therapeutic payloads containing genetic information to the airways of CF 
patients as their life expectancy and quality of life are mainly determined by the severity of 
lung diseases. Gene therapy is well-suited to the treatment of CF because the major target 
organ could be easily accessible via noninvasive topical application routes. The restoration of 
CFTR function in the airways could only be achieved when the wild-type CFTR gene is 
successfully delivered into the differentiated airway epithelial cells. Despite urgent needs for 
potent therapeutics, gene therapy for CF has been extensively investigated for decades and is 
still on the march through the windy road.  
 
Up to date, twenty-six clinical trials of CF gene therapy have been performed
39
. The majority 
of them were designed for “proof of concept” and to test the safety profiles. By the 
application of nonviral or viral-based approaches, two clinical trials of CF gene therapy were 
powered to evaluate the improvements of the lung conditions of CF patients
40,41
. The 
inefficient delivery of the exogenous therapeutic gene due to the limited understanding of 
numerous barriers existed within the pulmonary gene delivery, the transient gene expression 
and difficulties with repeat-dosing contribute to the limited success of CF gene therapy in 
clinical trials
42
. 
 
1.2.1 CF clinical trials with the utilization of viral vectors 
Adenovirus The first clinical trial for CF gene therapy was performed in 1993, just 4 years 
after the cloning of CFTR gene, when Zabner and colleagues adopted adenoviral vectors 
expressing functional CFTR to transfect the airway epithelial cells of CF patients. Although 
this study was not placebo controlled and the number of patients enrolled was low, this initial 
work proved that gene therapy is feasible regarding the correction of the Cl
-
 transport defect 
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among CF patients
43
. Based on this study, 9 clinical trials for CF gene therapy using 
adenoviral vectors have been performed in the following years
44–52
. Even though the 
adenoviral vectors hold the advantage of large packaging capacity, all the clinical trials based 
on this vector were failed due to the transient and low levels of gene expression. Apart from 
that, patients who receive adenoviral vectors tend to develop severe immune responses which 
in turn make the repeated-dosing impossible. All these disadvantages of adenoviral vectors 
suggest that they are unqualified candidates in the CF gene therapy field. However, many 
investigations aiming to address these disadvantages of adenoviral vectors have been 
performed. In order to enhance the cellular uptake of adenoviral vectors via increased 
interactions between adenoviral vectors and their receptors which are expressed in airway 
epithelium, sodium caprate which acts as a tight junction opener was applied
53,54
. In the effort 
to decrease the immune stimulating properties of adenoviral vectors, scientists optimized the 
viral coding sequences of adenoviral vectors based on immune suppressive strategies
55–57
. 
Nevertheless, all these improvements were just validated in pre-clinical studies. More 
investigations performed in the bacteria infected lungs of or CF patients are required to prove 
their efficiency. 
 
Adeno-associated viruses adeno-associated virus (AAV) belongs to a type of non-enveloped 
and nonpathogenic viral vector which contains a single-stranded DNA. AAV vectors are 
attractive candidates for CF gene therapy because they have a tropism to the lung and provide 
long-term gene expression. Clinical trial for CF gene therapy using AAV vectors initiated in 
1998 and followed with 5 other trials
40,58–62
. The results from all these clinical trials revealed 
that using AAV vectors for the transfecting the airways of CF patients is relatively safe, but 
their expression efficiency is still not enough to reach an obvious therapeutic effect
40,62
. The 
reason for their low transfection efficiency is the size limitation of packaging. A full-length 
functional promoter could not be integrated to drive the expression of the CFTR gene loaded 
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within the vectors because the packaging capacity of AAV vectors is limited to five kb
63
. 
Apart from the deficient transfection profile, AAV vectors also make the CF patients develop 
severe immune responses which significantly exclude the chances for repeated-dosing
59,60,62
. 
Although improvements towards overcoming the inherent limitations of AAV vectors  (such 
as immunogenicity and low transfection efficiency) have been done
64,65
, there is a report 
showing that AAV vectors may potentially integrate into the genome and the mitochondrial 
genome of recipient
66
. Even though such integration was found to be random, the safety 
issues related to the applications of AAV vectors in human studies still need to be carefully 
considered.   
 
Lentiviruses Up to date, there are no results of the clinical trial for CF gene therapy using 
lentiviral vectors yet, but the United Kingdom Cystic Fibrosis Gene Therapy Consortium is 
now preparing for a lentiviral vectors based phase I clinical trial for CF patients
1
, because the 
lentiviral vectors have shown promising results in many pre-clinical studies. The lentiviral 
vectors are ideal for transfecting the well-differentiated airway epithelial cells within CF 
patients as they contain RNA based genetic information which is suitable for the transfection 
of both dividing and nondividing cells
67
. Study using lentiviral vectors to transfect the airways 
of CF pigs indicated that in vivo gene transfection mediated by lentiviral vectors was very 
efficient
68
. Besides, lentiviral vectors are advantageous over the above-mentioned AAV and 
adenoviral counterparts because they do not result in significant inflammatory responses. 
Previous studies also revealed that lentiviral vectors are suitable for repeated-dosing
69–71
. 
Lentiviral vectors have been successfully applied in the treatments of Wiskott Aldrich 
syndrome as well as metachromatic leukodystrophy
72,73
, their long-term tolerability and safety 
profile have also been proved in Parkinson patients
74
. Despite all these promising profiles of 
lentiviral vectors, knowledge on their long-term systematical toxicity as well as the potential 
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possibility of insertional mutagenesis is still limited, and more evaluation should be 
performed before lentiviral vectors are translated into clinical applications for CF patients. 
 
1.2.2 CF Clinical trials with the utilization of nonviral-vectors 
Nonviral vectors are emerging and promising candidates for gene therapy. Increasing 
numbers of studies have adopted nonviral vectors to deliver in vitro transcribed messenger 
RNA (mRNA) or plasmid DNA (pDNA) in the theme of gene therapy
75,76
. Nonviral vectors 
could achieve the purpose of efficient in vivo delivery and controlled-release properties
77–79
, 
because they were biocompatible and can be easily adjusted to possess different properties. 
Nonviral vectors are typically composed of a genetic payload such as pDNA or mRNA 
encoding CFTR protein and a carrier system that can interact with and condense the genetic 
payload. The carrier system is generally derived from nature-product or biocompatible 
materials. The function of the carrier system is to increase the amount of functional nucleic 
acids payloads that being delivered to the target destination. This process could be facilitated 
by enhanced cellular uptake, efficient endosome escape and decreased nuclease degradation 
of the nucleic acids payloads etc
80
. The most commonly used carrier systems can be classified 
into cationic lipids and polymers. Cationic lipids have been used to deliver nucleic acids for 
decades. Nucleic acids payloads with negative charge could spontaneously interact with the 
positively charged lipids materials through the electrostatic force, the resulting complexes are 
named lipoplexes. Some previous studies revealed that cationic lipids are more advantageous 
in increasing the transfection efficiency of mRNA based genetic payloads compared with the 
cationic polymer-based delivery vehicles
81,82
. At the same time, numerous kinds of cationic 
polymers with different structures and properties have been synthesized and extensively 
applied as the delivery systems for the gene transfection
83,84
. Similar to the lipoplexes, the 
negatively charged nucleic acids payloads could readily complex with cationic polymers, 
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forming polyplexes that display improved stability compared with lipoplexes counterparts
80
. 
Many cationic polymer-based delivery systems have been optimized to an equal status of 
those well-established cationic lipid-based delivery systems, but cationic polymers with 
different structures may display completely different profiles of toxicity and transfection 
efficiency
85
. 
 
The first nonviral vectors based CF clinical trial was performed in 1995 by Caplen et al. Gill 
and colleagues conducted another CF clinical trial using the same type of nonviral vector two 
years later. Both of these two trials used liposomes consisting of  
dioleoylphosphatidylethanolamine/[N-(N′,N′-dimethylaminoethane)-carbomoyl]/cholesterol 
to deliver pDNA encoding CFTR via an intranasal route
86,87
. Results from these trials 
indicated that CFTR-pDNA could be successfully delivered to the airways of CF patients and 
the ion channel function regulated by functional CFTR can be partially detected, without the 
observation of significant immune responses and clinical adverse effects
86,87
. However, the 
scientists failed to observe a significant therapeutic benefit after the treatment due to the 
limited duration and extent of transgene expression
86
. In the following CF clinical trials using 
nonviral vectors, optimized formulations prepared by pDNA carrying CFTR encoding gene 
with EDMPC/Cholesterol liposome or GL67A liposome were investigated
41,88–92
. It turns out 
that GL67A-based formulation is the most promising candidate in terms of gene transfection 
for airway epithelia
93
. GL67A lipids based formulations also do not cause clinically adverse 
events
41
. This is precisely the reason why GL67A-based formulation was selected as the 
delivery vehicle in the most recent clinical trial for CF gene therapy
41
. Even though most of 
the nonviral-based CF clinical trials utilized cationic lipids based formulations, Konstan and 
colleagues adopted a cationic polypeptide based formulation to deliver pDNA encoding 
CFTR via single intranasal dosing to CF patients, they found this polypeptide based delivery 
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system displayed a comparable transfection efficiency with that achieved by the cationic 
lipids based formulation
94
.  
 
When compared with viral vectors, a huge advantage of nonviral vectors in the field of CF 
gene therapy is that they are suitable to repeated-dosing. Hyde et al. first revealed that three-
times repeated dosing of formulations consisted of pDNA encoding CFTR and cationic lipids 
via intranasal delivery did not compromise its transfection efficiency
95
. The most recent 
clinical trial also suggested that twelve repeated-dosing of formulations prepared by GL67A 
lipids and pDNA containing CFTR encoding gene once per month induced a stabilized lung 
function for CF patients, while the lung function of CF patients receiving placebo deteriorated 
after the investigated periods
41
. However, it should be noted that the expected endpoint, 
namely an improved lung function in the treatment group, was failed to be observed in this 
clinical trial but end up with a stabilized lung function with heterogeneous response among 
the CF patients
41
. This result indicated that the transfection efficiency and the consistency of 
the GL67A based formulation still need to be optimized. Meanwhile, the discovery and 
evaluation of next-generation genetic transfecting vectors into clinical trials should be actively 
pursued
41
.  
 
Except for the influence of delivery vehicles, the dosing route for administering nonviral 
vectors is also one of the critical parameters influencing the final results of CF gene therapy. 
Clinical trials for CF gene therapy being performed in the first decade utilized the nasal 
epithelium and maxillary sinus of CF patients as the surrogates which are similar to 
pulmonary epithelium in cell composition and are potentially safer for early-stage clinical 
trials
86–89
. However, the pulmonary epithelium lining the airway should be the primary target 
for a successful CF gene therapy. Alton and colleagues first conducted a pulmonary delivery 
of nonviral based formulations in 1999
90
 and followed by Ruiz et al.
92
, both of them observed 
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the correction of Cl
-
 transport defect in the lower airways of CF patients. Afterward, the 
pulmonary delivery route becomes the priority route when evaluating novel formulations for 
CF gene therapy. 
 
1.3 Potential next generation nonviral delivery systems for CF 
gene therapy 
 
The further development of delivery systems will be a key to the successful application of CF 
gene therapy in routine clinical practice. In the past decades, substantial advances have been 
achieved in the development of nonviral-based delivery systems for gene transfection. 
However, the vector design and mechanism understanding in this field are still limited.  
Continuous works are necessary to find more potent delivery vehicles which can provide high 
transfection activity and biocompatibility with minimal toxicity, high selectivity and 
specificity.  
 
As mentioned above, polyplexes and lipoplexes comprising therapeutic nucleic acids 
condensed within positively charged biomaterials have proved their gene transfecting efficacy 
in many in vitro investigations
96,97
. But these formulations may be problematic for some in 
vivo applications as they nonspecifically interact with irrelevant components (e.g., proteins or 
blood opsonins) or unrelated cells in biological fluids and tend to form aggregates in the 
physiological environment, leading to poor biodistribution, low in vivo efficiency and immune 
responses
98,99
. In contrast, some uncharged amphiphilic polymers were found to be useful 
substitutions in promoting in vivo gene delivery
100,101
. Among the massive numbers of 
amphiphilic copolymers with diverse chemical structures, poloxamine-based copolymers, 
comprising four poly(propylene oxide)/poly(ethylene oxide)/ (PPO/PEO) branches conjugated 
with an ethylenediamine moiety, represent an emerging and promising nonviral-based gene 
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delivery system, due to the ability of simultaneously exhibiting the properties of 
hydrophobicity and hydrophilicity
102
. The hydrophilic part (PEO) is able to create a sufficient 
interface with the aqueous surrounding while the hydrophobic parts (PPO) self-associate
103
.  
 
Poloxamines are typically synthesized via two steps. The propylene oxide (PO) blocks are 
first conjugated to the central ethylenediamine, then followed by the adding of ethylene oxide 
(EO) blocks, yielding in the tetrafunctional poly(ethylene oxide) terminated X-shape 
structure
103
. Poloxamines with a broad range of molecular weights (Mw) and EO/PO ratios 
are commercially available with the trademark of Tetronic
®
. The hydrophilic-lipophilic 
balance (HLB), The Mw and the EO/PO ratio of poloxamines strongly determine their 
capability to self-assemble and to undergo a solution-to-gel transition in physiological 
conditions, as well as their performance as drug/gene delivery vehicles
104–106
. Furthermore, 
the properties of the medium, especially the ionic strength and pH, also significantly influence 
the degree of protonation of the central ethylenediamine molecule, affecting the interactions 
between hydrophobic groups which finally determine the self-assembly process
103
. As a 
result, both stimuli responsiveness and structural parameters have huge impacts on their 
performance as drug or gene delivery systems. Poloxamines can be classified into three main 
categories according to the HLB values: i) highly hydrophobic; ii) medium hydrophilic and 
iii) highly hydrophilic 
103
. 
 
Poloxamines were first produced by BASF GmbH in the 1950s and subsequently have found 
a broad range of applications within the pharmaceutical and biomedical fields. Commercial 
utilization of such tetrafunctional block copolymers covers the field of washing solution for 
contact lens in a way that poloxamines are incorporated for the purpose of removing attached 
impurity and as a result to improve the compliance of users
107,108
, and the field of petroleum 
industry where poloxamines are applied as de-emulsifier and anti-foaming agents at high 
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concentrations
109,110
. The increasing knowledge in underlying mechanism and the self-
assembly properties under physiological conditions
111
, as well as the improvement of 
simplified methods for the accurate detection of target molecules within complexed 
samples
112,113
, have resulted in growing interest in poloxamines as drug delivery systems. As a 
result, poloxamines based block copolymers have been extensively applied in the biomedical 
fields as tissue scaffolds
114–119
, as components of transdermal formulations
120
, as adjuvants for 
DNA vaccination
121–123
, as structural elements for the polycation based nonviral vectors and 
for low Mw drugs delivery
111,124,125
. Although still few, the investigations performed in the 
gene delivery field have shown the potential of poloxamines as promising vehicles for in vivo 
applications. In the beginning, poloxamines were found to be the most potent vehicles by 
Prokop et al. in a screen of many synthetic and natural polymers for their ability to facilitate 
in vivo gene delivery into the subcutaneous tissue
126
. In the following studies, Pitard et al. 
revealed that intramuscular injection of DNA-poloxamine formulations, in both healthy mice 
and mice in pathological conditions, enhanced several folds the amount of recombinant 
protein produced with safety profiles, including luciferase, β-galactosidase, green fluorescent 
protein and therapeutic protein
102,127,128
. Besides, poloxamine based formulations were also 
suggested to be relevant as pulmonary gene transfer reagents
129
. 
 
A recent study revealed that intratracheal delivery of a formulation comprising poloxamine 
704 (T704) and pDNA in mice induced a better level of reporting gene expression in 
epithelial cells compared with that achieved with the “gold standard” GL67A-based 
formulation which was utilized in the latest CF gene therapy clinical trial
130
. Moreover, the 
level of immune response caused by the T704-mediated gene transfection was significantly 
lower compared with that associated with the GL67A-based formulation
130
. The authors also 
indicated that repeated dosing of the T704 formulation is feasible
130
. These results, together 
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with the fact that GMP-grade T704 is commercially available, highlight the application of the 
T704 copolymer as a promising non-viral gene transfer reagent for pulmonary gene delivery. 
1.4 Aims of the thesis 
 
While the in vivo gene transfection efficiency of poloxamine-based copolymers has been well 
proved
121,122,126
, their in vitro gene delivery profile is still poorly understood. To the best of 
our knowledge, apart from a few studies showing that poloxamine 904 increased the in vitro 
transfection efficiency of branched- or jet-polyethyleneimine-based polyplex (poloxamine 
904 acted as tissue engineering scaffolds) and the cellular uptake of poly (lactic-co-glycolic 
acid)-based polyplex
131–133
, none of the in vitro gene transfection profile of poloxamine-based 
copolymers has been systematically investigated. In a set of initial investigations, we found 
that neither pDNA nor in vitro transcribed messenger RNA (mRNA) could be transfected into 
cultured airway epithelial cells mediated by T704. These unexpected results suggested that 
T704 alone is not able to overcome various barriers posed by in vitro transfection, including 
cellular uptake, intracellular transport, endosome escape and nucleus import
134
. All these 
barriers significantly inhibit the exogenous genetic payloads from reaching its final 
destination where they take effect
135
. As a result, there are still huge unexplored potentials on 
the utilization of these tetrafunctional copolymers both in vitro and in vivo. We postulated that 
a significant improvement on the in vitro transfection efficiency by means of T704-based 
copolymer also promotes its in vivo transfection efficiency. Based on this hypothesis, we 
designed and developed a small library of short peptides comprising three functional moieties 
(Figure 1.4-1), namely 1) Anchor moiety containing hydrophobic moiety used to interact 
with PPO blocks of T704; 2) Cationic moiety consisting of several basic amino acids which 
are positively charged at neutral pH. The effect of this moiety is not only to efficiently 
condense nucleic acids but also facilitates an efficient endosomal escape; 3) Targeting moiety 
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comprising an amino acid sequence that direct the nucleic acid payloads to target cells or a 
specific subcellular compartment.  
 
Figure 1.4-1 Structures of the synthetic peptides and T704 used in this study. 
 
 
Figure 1.4-2 Schematic showing the complex formation. pDNA based binary complex (pDNA-BC) was 
formed by direct mixing of pDNA with T704; pDNA based ternary complex (pDNA-TC) was prepared via self-
assembly of the synthetic peptide, T704 and pDNA; mRNA based ternary complex (mRNA-TC) can be obtained 
in the similar way of the pDNA-TC counterpart. 
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Figure 1.4-3 Hypothetical pulmonary delivery process of pDNA-BC, pDNA-TC and mRNA-TC. Although 
all these nanocomplexes could overcome extracellular barriers in lung tissue by virtue of T704, pDNA-BC were 
prevented from entering target cells by various intracellular barriers, its pDNA payloads presumably translocate 
into cells via passive diffusion. In contrast, the synthetic peptide in ternary complexes affords the ability of 
efficient delivery of genetic payloads into target cells and organelles by addressing intracellular barriers. 
 
These peptides are expected to spontaneously form ternary complexes with the T704 
copolymer and nucleic acids via a simple self-assembly process (Figure 1.4-2), thus to 
address above-mentioned subcellular barriers (Figure 1.4-3). In the present study, we first 
confirmed the formation of ternary complexes and characterized their physicochemical 
properties. After clarifying the critical role of each moiety within peptide structure, the 
cellular uptake and the subcellular fate of ternary complex as well as binary counterpart 
(complex formed by T704 and nucleic acids) were evaluated and compared in order to prove 
the advantage of the ternary complex in terms of overcoming intracellular barriers. 
Subsequently, we assessed and optimized the in vitro transfection efficiency of pDNA or 
mRNA based ternary complexes consisting of different peptide candidates, and compared the 
most potent one with other prominent nonviral gene transfer reagents regarding the 
transfection efficiency and toxicity. In a second phase, intratracheal application of ternary 
complex containing mRNA or pDNA into CF mice further demonstrated the superiority of 
ternary complex compared with either binary complex or cationic lipid-based formulations. 
Finally, we evaluated the capability of the ternary complex in the delivery of Sleeping Beauty 
(SB)-based transposon system consisting of SB-transposon (pDNA) and transposase-encoding 
SB100X-mRNA (As a transient source of transposase to avoid transposon re-integration) for 
in vivo long-term restoration of CFTR. Although previous studies established long-term gene 
expression within the lung of mice via intravenous delivery
136,137
, gene transfer by this route is 
confined within pneumocytes and alveolar endothelial cells due to the vector entrapment
138
. In 
terms of gene therapy for CF, genetic payloads have to be targeted to the pulmonary epithelia 
lining the airway which are the primary sites of CFTR expression
138
.  
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2 MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Reagents 
Poloxamine 704 (T704) was kindly provided by InCellArt (Nantes, France). Poloxamine 304 
(T304) and poloxamine 904 (T904) were generous gifts from BASF GmbH (Ludwigshafen, 
Germany). Poloxamine 90R4 (T90R4), poloxamer 184 (L64) and were obtained from Sigma-
Aldrich Chemie GmbH (Munich, Germany). Lipofectamine2000 was obtained from 
Invitrogen (Schwerte, Germany). A mixture (at the molar ratio of 1:1) of 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammoniumpropane 
(DOTAP)  in chloroform was obtained from Avanti Polar Lipids (Alabaster, Alabama, USA). 
4,6-diamidino-2-phenylindole (DAPI) and LysoTracker
®
 Red DND-99 were purchased from 
Life technologies GmbH (Karlsruhe, Germany). Branched polyethyleneimine (brPEI, average 
MW= 25kDa), lipoic acid, myristic acid, cholesteryl chloroformate, heparan sulfate and 3-(4,5-
Dimethyl-2-tetrazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) were all obtained from 
Sigma-Aldrich (Munich, Germany). CFTR antibodies were provided by Dr. John Riordan (the 
University of North Carolina at Chapel Hill). D-Luciferin was purchased from Synchem 
(Felsberg/Altenburg, Germany). Fmoc and Boc protected amino acids, piperidine, 2-Chlorotrityl 
chloride resin, trifluoroacetic acid (TFA) and N,N-diisopropylethylamine (DIPEA) were obtained 
from Iris Biotech (Marktredwitz, Germany). All other solvents and small molecular reagents were 
obtained in high quality (analytical or HPLC grade) from Sigma-Aldrich (Munich, Germany). 
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2.1.2 Nucleic acids  
Stabilized, non-immunogenic messenger RNA (SNIM mRNA) encoding metridia luciferase 
(MetLuc-mRNA), SNIM mRNA encoding enhanced green fluorescent protein (EGFP), SNIM 
mRNA encoding firefly luciferase (fLUC-mRNA) and SNIM mRNA encoding Sleeping 
Beauty (SB) transposase (SB100X-mRNA) were kindly provided by ethris GmbH (Planegg, 
Germany). Plasmid DNA encoding metridia luciferase (MetLuc-pDNA) was provided by 
Prof. Dr. Christian Plank (Technical University of Munich, Germany). SB-based plasmids, 
pGM206-fLUC-CFTR/T2 which contains a T2 SB transposon encoding both firefly luciferase 
and Cystic Fibrosis Transmembrane Conductance Regulator, were constructed by the group 
of Dr. Zoltan Ivics (Paul-Ehrlich-Institute, Langen, Germany). EGFP-pDNA was purchased 
from Plasmid Factory (Bielefeld, Germany). Fluorescein labelled plasmid DNA (Fluo-pDNA) 
was obtained from Mirus (Goettingen, Germany).  
 
2.2 Methods 
2.2.1 Synthesis of peptides 
All peptides were produced by Fmoc solid phase peptide synthesis. Briefly, the solid phase  
was 2-Chlorotrityl chloride resin. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU) was used as the coupling reagent and N,N-
diisopropylethylamine (DIPEA) served as the base. Lipoic acid, myristic acid or cholesterol 
was coupled to the peptides before deprotection and cleaving. The peptides were subsequently 
cleaved from the resin by incubation in dichloromethane methylene 
chloride/trifluoroethanol/acetic acid (70/20/10, v/v/v) at RT for 2 h. The resin was filtrated, 
and the solvent was removed by evaporation. After deprotection with trifluoroacetic 
acid/water/phenol/triisopropylethylamine (88:5:5:2) at RT for 2 h, the yield solution was 
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added into diethyl ether on ice for precipitation. The final peptides were purified using 
reverse-phase HPLC. The molecular weight (Mw) of peptides was confirmed by liquid 
chromatography-mass spectroscopy (LC/MS).  
 
2.2.2 Cell culture 
BEAS-2B (human bronchial epithelial cell line) cells were obtained from the ATCC 
(American Type Culture Collection, Wesel, Germany) and were cultured in RPMI 1640 
medium (Gibco, Germany) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Gibco, Germany) and 1% (v/v) penicillin/streptomycin  (Gibco, Germany). 16HBE (human 
bronchial epithelial cell line) cells were generously provided by Prof. Dr. Dieter C. Gruenert 
(University of California at San Francisco, CA, USA) and were cultured in Eagle’s Minimal 
Essential Medium (Gibco, Germany) with 10% heat-inactivated FBS (Gibco, Germany)  and 
1% (v/v) penicillin/streptomycin  (Gibco, Germany) at 37 ℃ and 5% CO2. CFBE-WT cells 
expressing wild-type CFTR and CFBE-delF cells which contain the most common CF 
phenotype causing mutation (Phe508del) were obtained from Gregory Fleming James Cystic 
Fibrosis Research Center (University of Alabama at Birmingham) and were cultured in the 
same Eagle’s Minimal Essential Medium as described above. All experiments were 
performed on cells in the logarithmic growth phase. 
 
2.2.3 Preparation of mRNA/pDNA based binary and ternary 
complexes 
Stock solution of T704 (5 mg/ml) and peptide (1 mg/ml) were prepared in nuclease-free water 
(NF-water) and stored at 4 ℃. Binary complex (T704/mRNA or T704/pDNA) was prepared 
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by mixing equal volumes of diluted T704 stock solution with mRNA or pDNA solution at the 
desired concentration in 2X Tyrode’s solution102. Peptide-based binary complex was prepared 
in the same way in NF-water. Ternary complex was formulated via two-steps incubation. 
Briefly, T704 solution at a particular concentration (always be defined as weight/weight ratio 
of T704 to nucleic acids) in NF-water were mixed with equal volume of peptide solution at a 
specific concentration (defined as N/P ratio, namely the ratio between nitrogen residues in 
peptide and nucleic acids phosphate groups). After 20 min incubation at room temperature 
(RT), the same volume of nucleic acid (mRNA or pDNA) solution in NF-water was added to 
the above T704/peptide solution and mixed gently by pipetting up and down several times. 
Subsequently, the complex was incubated for another 20 min at RT prior to further use. 
mRNA or pDNA solution in NF-water was complexed with brPEI (25kDa) at an optimum 
N/P ratio, the resulting complex served as a control polyplex. As for control lipoplex, 
Lipofectamine2000 complex was prepared according to the manufacturer’s instructions using 
the optimum concentration. In order to prepare DOTAP/DOPE liposomes, a lipid film was 
formed by removing the chloroform solvent in DOTAP/DOPE mixture solution under 
nitrogen atmosphere. The lipid film is hydrated with NF-water to make the final concentration 
of 10 mM DOTAP/DOPE. The DOTAP/DOPE liposome formulation was formed by mixing 
250 µl of pGM206-fLUC-CFTR/T2 (150 µg) solution and 250 µl diluted DOTAP/DOPE 
solution (190 µl of 10 mM DOTAP/DOPE liposome and 60 µl NF-water). The mix solution 
was incubated at RT for 20 min before further use.   
  
2.2.4 Size and zeta potential measurements 
Particle size and zeta potential measurements of binary and ternary complexes were 
performed using a Zetasizer Nano ZS (Malvern Instruments Ltd.) at 25 ℃. The binary 
complex was prepared at a weight/weight ratio (T704/mRNA or pDNA) of 63:1. Ternary 
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complex was prepared with T704 at a weight/weight ratio of 63:1 and peptide at optimum N/P 
ratio using methods described above. The mRNA and pDNA concentration in both binary and 
ternary complexes was fixed at 10 µg/ml. 
 
2.2.5 Transmission electron microscopy  
Transmission electron microscopy (FEI Tecnai G2 F20 STWIN) was used to observe the 
morphology of both binary and ternary complexes. The complexes were freshly prepared 
using methods described above and dropped onto Quantifoil holey carbon foil (Micro Tools 
GmbH, Germany) to obtain the images. The concentration of T704 and nucleic acids (mRNA 
or pDNA) were fixed at 0.25% (w/v) and 0.2 µg/µl in both binary and ternary complexes. 
Peptide 9 at N/P ratio of 5 was applied in ternary complexes. 
 
2.2.6 Agarose gel retardation assay  
The extent of mRNA and pDNA condensation in binary and ternary complexes was 
investigated by electrophoresis on a 1% agarose gel containing 1 µg/ml ethidium bromide. 
Briefly, T704 at the concentration of 63 (w/w, relative to nucleic acids) and mRNA or pDNA 
were used to prepare binary complexes. Peptides at varying N/P ratios (1 to 6) were used to 
form ternary complexes with T704 at the concentration of 63 (w/w) and mRNA or pDNA. 
200 ng mRNA or pDNA were added per well. To all samples, 3 µl of 6 X loading buffer 
(0.25% w/v bromphenol blue, 0.25% xylene cyanol FF, 30% glycerol in water) was added 
before loading the samples onto the gel in Tris-acetate-EDTA (TAE) buffer at 120 V for 60 
min. The stability of binary and ternary complexes was examined by DNase I (ThermoFisher 
Scientific, Karlsruhe, Germany) digestion followed by agarose gel electrophoresis. 3 µg 
pDNA was complexed with T704 at the concentration of 63 (w/w) to prepare pDNA/T704 
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binary complex, pDNA/T704/peptide 9 ternary complex was prepared with additional peptide 
9 at N/P ratio of 5. The complexes were incubated with 2.5, 5, and 10 U DNase I for 1 h at 37 
℃. After phenol/chloroform extraction the pDNA was precipitated with ethanol overnight and 
air-dried, and the pellet was re-dissolved in NF-water. The DNA was transferred on a 1% 
agarose gel containing 1 µg/ml ethidium bromide. The binding strength of nucleic acids 
within the ternary complex was evaluated by heparan sulfate (HS) competition assay. Briefly, 
pDNA/T704/peptide 9 or mRNA/T704/peptide 9 ternary complex (with the same 
composition) was incubated with different amounts of HS at RT for 45 min, the resultant 
samples were resolved by agarose gel electrophoresis as above described.     
 
2.2.7 In vitro transfection 
For the luciferase assay, cells were seeded at a density of 1.8 x 10
4
/well (BEAS-2B) or 3.5 x 
10
4
/well (16HBE) in 96-well plates 24 h before transfection to reach 60-80% confluence. 
Following removal of growth medium, cells were rinsed with DPBS (Gibco, Germany). 170 
µl of fresh serum-free OptiMEM (Gibco, Germany) were added per well, subsequently 30 µl 
of complexes containing mRNA or pDNA, prepared as described above (corresponding to 
400 ng mRNA or pDNA per well), was added in replicates of five. After 4 h of incubation at 
37 ℃ in a humidified atmosphere containing 5% CO2, the transfection medium was replaced 
with culture medium supplemented with 10% FBS and 1% (v/v) penicillin/streptomycin. 
Luciferase activity in 50 µl supernatants from transfected cells was assayed with 30 µl 
Metridia luciferase substrate (coelenterazine, Invivogen, France) at predetermined time point 
using a FLUOstar microplate reader (BMG Labtech, Germany) and relative light units (RLU) 
was used to express its activity. The cell culture medium was replaced with fresh one every 
day after sampling. 
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For enhanced green fluorescent protein (EGFP) expression, cells were seeded at a density of 
6.8 x 10
4
/well (BEAS-2B) or 7.0 x 10
4
/well (16HBE) in 8-well slides (ibidi GmbH, Munich, 
Germany) 48 h before transfection to reach a monolayer (90-100% confluence). EGFP-
mRNA at the dose of 600 ng/well was used to prepare complexes for transfection. The 
transfection procedure was the same as described above. 24 h after transfection, cells were 
evaluated by means of a fluorescence microscopy (Zeiss Axiovert 200 M, Carl Zeiss 
Microscopy GmbH, Germany). 
 
2.2.8 Nebulization study 
Nebulization experiments were conducted using a PARI Boy
®
 Nebulizer (PARI GmbH, 
Germany)
139
. Briefly, a fraction of complexes was kept apart and used as a “non-nebulized” 
control. The remaining solution was aerosolized for 5 minutes by employing PARI Boy
®
 
Nebulizer. The nebulized aerosol was collected in a separate tube. “Non-nebulized” control, 
collected solution (nebulized) and those remain in the nebulizer (reservoir) was incubated 
with pre-seeded BEAS-2B cells and 16HBE cells in 96-well plates for 4 h at 37 ℃ in a 
humidified atmosphere. Luciferase activity in 50 µl of supernatants was assayed 24 h, 48 h, 
and 72 h after transfection and its activity is expressed in RLU. The cell culture media was 
replaced each day after sampling. 
 
2.2.9 Flow cytometry 
To quantitatively determine the percentage of transfected cells expressing EGFP, EGFP-
mRNA or EGFP-pDNA was complexed with T704 at the concentration of 63 (w/w) and 
peptide 9 at the N/P ratio of 5 to form ternary complexes. Lipofectamin2000 at a 
concentration of 6.7 µl/well and brPEI at N/P ratio of 20 were used as lipoplex and polyplex 
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control. The amount of EGFP-mRNA or EGFP-pDNA in each sample was 4 µg/well. Then 
the complexes were incubated for 4 h with BEAS-2B cells (6 x 10
5
/well) or 16HBE cells (7.5 
x 10
5
/well) which were pre-seeded in 6-well plate 24 h before transfection. Cells were harvest 
24 h (EGFP-mRNA transfection) or 48 h (EGFP-pDNA transfection) after transfection and 
suspended in a flow buffer (Sigma-Aldrich, Munich, Germany). 7-AAD (eBioscience, 
Germany) staining was used to exclude dead cells. 10 000 live cells per sample were analyzed 
by flow cytometry (FACS LSRFortessa, BD Bioscience, Germany). Data were analyzed with 
FLOWJO (Version 9.8.3, FlowJo LLC, USA).   
 
In order to study the cellular uptake of T704-based binary and ternary complexes, 16HBE 
cells (7 x 10
5
/well) were seeded in 6-well plate 24 h before investigation. Binary complex and 
ternary complex containing Fluo-pDNA were prepared as described above. The amount of 
Fluo-pDNA in each sample was 4 µg/well. Naked Fluo-pDNA served as a negative control 
formulation. After 4 h incubation, the medium was removed. The cells were harvested and 
rinsed with cold PBS for three times followed immediately by flow cytometry analysis. The 
amount of 10 000 live cells were collected for each sample.  
 
With the purpose of identifying possible internalization mechanism of the ternary complex, 
16HBE cells were pre-incubated at different temperatures or treated with specific reagents at 
37 ℃ for 1 h, then incubated with the ternary complex under the same conditions for another 
4 h. (I, II) To study the effects of clathrin- and caveolae-mediated endocytosis, 10 µg/ml 
chlorpromazine or 1 µg/ml filipin in OptiMEM was used. (III) To examine the effect of 
macropinocytosis mediated endocytosis, 0.5 mM amiloride was added. (IV) To study the 
adsorptive mediated endocytosis, 1 mM protamine sulfate was applied. (V) Cells were pre-
incubated with 35 mM sodium chlorate in cell culture medium for 24 h to investigate the 
effect of desulfurization, (VI) To examine the effect of an active transport inhibitor, sodium 
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azide dissolved in OptiMEM at the concentration of 0.5 mg/ml was incubated with cells. (VII) 
To study the influence of temperature on endocytosis, the experiment was carried out at 4 ℃. 
(VIII) Excess amount of free peptide 0 (0.01 µg/µl), K4R4 peptide (cationic fragment of 
peptide 0, 0.005 µg/µl)), lipoic acid (0.0008 µg/µl) or nuclear localization signal (NLS, 
0.0035 µg/µl), were used as potential receptor-mediated endocytosis competitor for peptide 0 
based ternary complex. In addition, peptide 0 based ternary complex transfected cells without 
any other treatments were used as the positive controls. (IX) To study the receptor-mediated 
endocytosis of peptide 9 based ternary complex, excess amount of free peptide 9 (0.02 µg/µl), 
“KWET” peptide (hydrophobic moiety of peptide 9, sequence: 
KETWWETWWTEWWTEW, 0.009 µg/µl), or “ligand” (targeting moiety of peptide 9, 
sequence: GACSERSMNFCG, 0.005 µg/µl), were used as receptor-mediated endocytosis 
competitors. The cellular uptake of non-treated peptide 9 based ternary complex was used as 
the control. The results are shown as relative uptake rate of different groups which normalized 
according to the positive control group. 
 
2.2.10 Confocal microscopy 
16HBE cells at the density of 4 x 10
5
/well were seeded in 6-well plate 24 h before 
investigation. Binary complex and ternary complex containing Fluo-pDNA (T704/peptide 0/ 
Fluo-pDNA) were prepared as described above. The amount of Fluo-pDNA in each sample 
was 3 µg/well. LysoTracker
®
 Red DND-99 was applied as endocytic vesicles marker 
according to the manufacturer’s instructions. After 4 h incubation, cells were rinsed with cold 
PBS three times. DAPI was added to visualize the nuclei 10 min before imaging. The cells 
were mounted with anti-fade medium and imaged on a confocal laser scanning microscope  
(CLSM , Carl Zeiss LSM 510, Jena, Germany). 
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2.2.11 Cytotoxicity assay  
The effect of T704, peptide 9, Lipofectamine2000 and brPEI (25 kDa) at different 
concentrations on the cell viability of BEAS-2B and 16HBE cells was evaluated using a MTT 
assay as described in
139
. Meanwhile, the cytotoxicity of T704/peptide 9/pDNA ternary 
complex (prepared under the condition showing highest transgene expression) against BEAS-
2B and 16HBE cells were investigated and compared with Lipofectamine2000-based and 
brPEI-based counterparts using the same assay, 24 h after the transfection. Cell viability was 
calculated as a relative value (in %) compared to the control, untransfected cells. 
 
2.2.12 Animal studies 
All in vivo studies were performed according to the guidelines of German animal welfare law 
and were authorized by the local ethics committee and animal welfare authorities. B6cf mice 
(between 20-30 weeks of age) were obtained from the laboratory of Hans J Hedrich 
(Hannover, Germany) and kept under specific pathogen-free conditions undergoing a 12 h/12 
h light/dark cycle with free access to food and water. Animals were conceded an adaption 
time of at least 7 days prior to the beginning of experiments. For all experiments, the animals 
were anesthetized with a mixture of medetomidine (0.5 mg/kg), midazolam (5 mg/kg) and 
fentanyl (0.05 mg/kg), injected intraperitoneally. For intratracheal dosing, mice received the 
formulations via a high-pressure MicroSprayer device as described before
77
. For 
bioluminescence imaging, mice were anesthetized and followed by injection of the substrate 
D-luciferin (1.5 mg/50 ml PBS per mouse) intraperitoneally. Bioluminescence was measured 
10 min later using a Xenogen IVIS In Vivo Imaging System 100 (Caliper Life Sciences, 
California, USA).  
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Transfection of mRNA-based formulations. After anesthesia, 10 µg fLUC-mRNA formulated 
with 0.25% T704 (Binary complex) or 0.25% T704/Peptide 9 (N/P = 5) (Ternary complex) in 
a final volume of 50 µl, was intratracheally administered to one mouse. NF-water (50 
µl/mouse) treated mice were used as negative controls. Lungs were excised 24 h post dosing 
and the bioluminescence intensity was measured.   
 
Transfection of pDNA-based formulations. pGM206-fLUC-CFTR/T2 formulated with 0.25% 
T704 (Binary complex) or 0.25% T704/Peptide 9 at N/P ratio of 5 (Ternary complex)  or 
DOTAP-based cationic lipids (Lipoplex), was intratracheally administered (50 µl/mouse) to 
anesthetized mice. All formulations contained 15 µg pDNA/mouse. Mice which received NF-
water (50 µl/mouse) were studied as negative controls. Luciferase activity was determined 48 
h post dosing.  
 
Transfection of SB transposon system-based formulations for long-term gene expression. 
Ternary complex comprising pGM206-fLUC-CFTR/T2 (15 µg/mouse), 0.25% T704 and 
peptide 9 (N/P = 5) was administered to anesthetized mice intratracheally (50 µl/mouse). 
After 15 min, mice received another formulation (25 µl/mouse) consisting of SB100X-mRNA 
(10 µg/mouse), 0.25% T704 and peptide 9 (N/P = 5). Mice treated with single dose of 
pGM206-fLUC-CFTR/T2-based or SB100X-mRNA-based formulations were applied as 
controls. All mice received repeated-dosing in an interval of 5 days (three times in total). 
Luciferase activity was measured at predetermined time points. 
 
 
Materials and Methods 
30 
2.2.13 Histology 
To detect pathohistological signs of inflammation, lung (or trachea) tissues were obtained 
from mice 48 h after intratracheal dosing of pDNA-based binary complex or ternary complex 
or DOTAP-based lipoplex as described above. Lung tissues were filled with Tissue-Tek® 
O.C.T.™/PBS (1:10), fixed in 4% formalin and embedded in paraffin. Tissue sections (5 µm) 
were stained by Haematoxylin-Eosin and evaluated using light microscopy. 
 
2.2.14 Immunohistochemical analysis 
 Lung tissue cryosections were fixed in acetone at -20°C for 10 minutes and air dried. After 
incubation in 10% donkey serum 100 µl primary antibody mixture was applied to the section. 
Antibodies detecting CFTR (“570”, University of North Carolina at Chapel Hill) and ZO1 
(Abcam, ab99462) were used at dilutions of 1:100 and 1:200 respectively. After incubation at 
RT for 1h, excess primary antibody was removed in washing buffer. A mixture of 100µl 
secondary antibodies labelled with Cy3 (donkey anti mouse, 1:500) and Alexa488 (donkey 
anti goat, 1:200), incubated for 1h, were used for detection. Stained slides were washed in 
washing buffer and demineralized water and mounted with medium containing 
Prolong/DAPI. All images were obtained on an automated digital fluorescence microscope 
(Keyence BZ-9000) at 40x magnification using filters appropriate for the chosen indicators. 
Image post-processing (linear intensity adjustment, merging) was performed with Affinity 
Photo (version 1.5.1.54) and Affinity Designer (version 1.5.2.58). 
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2.2.15 Statistics 
Unless otherwise specified, all the experiments were repeated at least two other occasions 
with 5 or more replicates to ensure the reproducibility of the data. Data for all bar charts were 
plotted using means and error bars that correspond to standard deviations. Statistical analysis 
was performed using Prism 7 (GraphPad Software Inc, USA). Dual comparisons were made 
using the Student's t-test and comparisons between multiple conditions were analyzed using 
ANOVA. All the tests were two-tailed. Significant differences were defined as *: p < 0.05; 
**: p < 0.01; ***: p < 0.005; ****: p < 0.001; *****: p < 0.0001; N.S. meant not significant. 
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3 RESULTS 
3.1 Establishing poloxamine 704 (T704)-peptide ternary 
complexes 
3.1.1 T704 based binary complexes were invalid for in vitro 
transfection 
Although poloxamine copolymers have shown their efficiency as non-viral gene delivery 
vectors in many in vivo applications
102,121,122,126,127,130
, we surprisingly recognized that these 
promising block copolymers are rather poor transfection reagents in delivering nucleic acids 
into cultured cells. Data obtained from in vitro transfection on human bronchial epithelial 
cells (BEAS-2B and 16HBE) revealed that transfection efficiency of T704-based binary 
complexes (unless otherwise mentioned, always refers to nanocomplexes formed by T704 and 
nucleic acids in following paragraphs) formed by in vitro transcribed messenger RNA 
encoding Metridia Luciferase (MetLuc-mRNA) and a broad range of T704 was all lower than 
600 relative light units (RLU), which was similar to the intensity of background signal 
(Figure 3.1-1a). Binary complexes containing plasmid DNA encoding Metridia Luciferase 
(MetLuc-pDNA) also showed similar transfection efficiency under the same conditions 
(Figure 3.1-1b). 
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a  
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Figure 3.1-1 In vitro transfection profile of T704 based binary complexes in cultured human bronchial 
epithelial cells (BEAS-2B and 16HBE). (a) 400 ng/well MetLuc-mRNA was complexed with T704 at different 
concentrations from 2.5 to 200 (w/w, the concentration of T704 is always defined as the weight to weight ratio of 
T704 to nucleic acids in the following text) in Tyrode’s solution. After 30 min incubation at room temperature 
(RT), samples were added into 96-well plate containing pre-seeded cells and incubated with cells in OptiMEM 
(without serum and antibiotics) for 4 h at 37 ℃ in a humidified atmosphere (95% air, 5% CO2). Luciferase 
activity in 50 µl supernatants from transfected cells was assayed after 24 h and its activity was expressed in 
relative light units (RLU). (b) MetLuc-pDNA/T704 binary complexes were prepared in the same way of mRNA 
counterpart. Luciferase activity in 50 µl supernatants from transfected cells was measured at 24 h, 48 h, 72 h and 
96 h after transfection and its activity was expressed in RLU. Supernatants from non-treated cells were used as 
the background samples. All experiments were performed at least three times. Data represent the mean ± 
standard deviation (SD) (n>5). 
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3.1.2 Investigations on parameters influencing in vitro transfection 
efficiency of ternary complex 
In order to enable in vitro transfection of T704-based copolymers, a small library (Table 3.1) 
of synthetic peptides comprising three different functional moieties was developed to form 
ternary complexes (unless otherwise mentioned, always refers to nanoparticles formed by 
T704/peptide/nucleic acid in following paragraphs) with T704 and nucleic acids. Apart from 
the extensively studied pDNA molecules, the attractive and rapidly emerged mRNA 
therapeutics were also evaluated in current study
140,141
. 
 
Table 3.1. The structure of all synthetic peptides used in current study. 
 
Name Sequence 
Peptide 0 Lipoic acid-WKKRRRRKKVKRKKKP  
Peptide 1 KKRRRRKKVKRKKKP 
Peptide 2 Lipoic acid 
Peptide 3 Lipoic acid-WKKRRRRKKVKRKTKP  
Peptide 4 Lipoic acid-WKKKKRRRRRKKKKGACSERSMNFCG 
Peptide 5 Lipoic acid-WKKKKRRRRRKKKKGACYGLPHKFCG 
Peptide 6 Lipoic acid-WKKRRRRRRRRRKKGACSERSMNFCG 
Peptide 7 Lipoic acid-WKKRRRRRRRRKKGACYGLPHKFCG 
Peptide 8 Lipoic acid-WLHHHKKLLHHHKKLGACSERSMNFCG 
Peptide 9 KETWWETWWTEWWTEWKKKKRRRRRKKKKGACSERSMNFCG 
Peptide 10 VVVVVVKRRRRKGACSERSMNFCG 
Peptide 11 C13H27CONH-KKKKRRRRRKKKKGACSERSMNFCG 
Peptide 12 Cholesteryl-KKKKRRRRRKKKKGACSERSMNFCG 
Sequences given in italics are targeting moieties. Underlined sequences represent anchor moieties. Sequences 
given in bold represent cationic moieties.    
 
We started from a prototype (peptide 0), comprising lipoic acid (LA, produced naturally in the 
human body and represents a well-accepted medical materials
142
) which acts as anchor 
moiety, cationic moiety containing lysine/arginine and nuclear localization signal (NLS) at 
the position of targeting moiety, to investigate parameters influencing in vitro transfection 
efficiency of ternary complex in bronchial epithelial cells. As shown in Figure 3.1-2, the 
mRNA expression increased with an enhanced concentration of T704 or an enhanced N/P 
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ratio (the ratio between nitrogen residues in peptide and nucleic acids phosphate groups) of 
peptide 0, reaching maximum when T704 concentration = 63 (w/w, relative to mRNA) and 
peptide 0 N/P = 10. Then the mRNA expression progressively declined at higher T704 
concentrations and higher N/P ratios of peptide 0. In terms of pDNA based ternary complex, a 
similar tendency of transfection efficiency could be observed (Figure 3.1-3). However, the 
optimum concentration of T704 and peptide 0 within ternary complex showing highest pDNA 
expression was cell line dependent. Ternary complex consisted of T704 at concentration of 50 
(w/w) and peptide 0 at N/P = 30 showed highest transfection rate in BEAS-2B cells (Figure 
3.1-3), whereas counterparts comprising T704 at concentration of 63 (w/w) and peptide 0 at 
N/P = 20 showed the highest transfection efficiency in 16HBE cells (Figure 3.1-3). Besides, 
we also found that the peptide 0 alone is not capable of mediating efficient nucleic acids 
transfection (Figure 3.1-4), emphasizing the superiority of ternary complex. 
 
a  
b  
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Figure 3.1-2 Investigations on parameters influencing in vitro transfection efficiency of the ternary 
complex. (a) The influence of T704 concentration (w/w, relative to nucleic acids) on the transfection of MetLuc-
mRNA based ternary complex in BEAS-2B and 16HBE cells. The N/P ratio of peptide component within 
ternary complex was fixed at 10; (b) The effect of peptide 0 concentration on the transfection efficiency of 
MetLuc-mRNA based ternary complex in BEAS-2B and 16HBE cells. The concentration of T704 component 
within ternary complex was fixed at 63 (w/w, relative to nucleic acids); Luciferase activity in 50 µl supernatants 
from transfected cells was assayed after 24 h and its activity was expressed in RLU. All experiments were 
performed at least three times. The data are given as the mean ± SD (n>5). 
 
 
 
 
a  
b  
Figure 3.1-3 Investigations on parameters influencing in vitro transfection efficiency of the ternary 
complex. (a) Transfection efficiency of MetLuc-pDNA based ternary complexes consisting of different 
concentrations of T704 in BEAS-2B and 16HBE cells. The N/P ratio of peptide component in the case of BEAS-
2B cells transfection was 30 and in the case of 16HBE cells transfection was 20; (b) Evaluation of MetLuc-
pDNA expression mediated by ternary complexes comprising different concentrations of peptide 0 in BEAS-2B 
and 16HBE cells. The concentration of T704 component in the case of BEAS-2B cells transfection was 50 (w/w) 
and in the case of 16HBE cells transfection was 63 (w/w); Luciferase activity in 50 µl supernatants was 
measured 24 h, 48 h and 72 h after transfection and its activity was expressed in RLU. All experiments were 
performed at least three times. The data are given as the mean ± SD (n>5). 
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a  
b  
Figure 3.1-4 In vitro transfection profile of peptide 0 based binary complexes in cultured human bronchial 
epithelial cells (BEAS-2B and 16HBE). (a) 400 ng/well MetLuc-mRNA was complexed with peptide 0 at 
different N/P ratios from 5 to 15 (relative to nucleic acids) in nuclease-free water (NF-water). After 30 min 
incubation at RT, samples were added into 96-well plate containing pre-seeded cells and incubated with cells in 
OptiMEM (without serum and antibiotics) for 4 h at 37 ℃ in a humidified atmosphere (95% air, 5% CO2). 
Luciferase activity in 50 µl supernatants from transfected cells was assayed after 24 h and its activity was 
expressed in RLU. (b) MetLuc-pDNA/peptide 0 binary complexes were prepared in the same way of mRNA 
counterpart, luciferase activity in 50 µl supernatants from transfected cells was measured 24 h, 48 h, 72 h and 96 
h after transfection and its activity was expressed in RLU. Supernatants from non-treated cells were used as the 
background samples. All experiments were performed at least three times. The data are given as the mean ± SD 
(n>5).  
 
Based on these results, we further evaluated other parameters that affect the transfection 
efficiency of the ternary complex using MetLuc-mRNA as a reporter to transfect 16HBE 
cells. Transfection efficiency of ternary complex was significantly influenced by the mRNA 
concentration (Figure 3.1-5a), the method of preparation (Figure 3.1-5b), the complex 
forming medium (Figure 3.1-5c) and the incubation time (Figure 3.1-5d). Therefore, we 
fixed the following parameters for all in vitro transfections of ternary complex: i) the 
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concentration of mRNA or pDNA in ternary complex was fixed at 400 ng/well (relative to 96-
well plate); ii) ternary complex was prepared by first mixing equal volume of T704 and 
peptide stock solution, followed by adding equal volume of mRNA or pDNA solution; iii) 
ternary complex was consistently prepared in nuclease-free water (NF-water); iv) ternary 
complex was incubated with cultured cells for 4 h in consideration of transfection efficiency 
and cytotoxic side-effect. 
 
a   b  
c   d  
Figure 3.1-5 Investigations on parameters influencing in vitro transfection efficiency of the ternary 
complex. The transfection efficiency of mRNA based ternary complexes depending on (a) the concentration of 
mRNA in ternary complexes; on (b) different methods of complex preparation: Method 1: T704 and peptide 0 at 
optimum concentration were first mixed and incubated for 20 min, followed by adding of equal volume of 
mRNA solution with another 20 min incubation at RT. Method 2: in the first step, T704 and mRNA solution 
were mixed and incubated for 20 min incubation at RT, an equal volume of peptide 0 were added and incubated 
for another 20 min at RT in the second step. Method 3: peptide 0 was complexed with mRNA by 20 min 
incubation at RT, then an equal volume of T704 solution was introduced and incubated for another 20 min to 
form the ternary complex; on (c) different media used in the complex preparation; and on (d) incubation time 
with 16HBE cells. Luciferase activity in each assay was measured 24 h after transfection. The results represent 
the mean ± SD of three independent experiments. 
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3.2 Characterization of ternary complexes and binary 
counterparts 
3.2.1 Agarose gel retardation assay 
We analyzed the capacity of ternary complexes comprising different peptides to condense 
mRNA or pDNA by agarose gel retardation assay. As shown in Figure 3.2-1, all ternary 
complexes (except peptide 2-based ternary complexes because there is no positively charged 
amino acid within peptide 2, data not shown) can efficiently condense mRNA (Figure 3.2-1a) 
or pDNA (Figure 3.2-1b) when the N/P ratio of peptide component was above 3 (for peptide 
12, the N/P ratio should be above 5). However, T704 at the same concentration alone was not 
able to retard mRNA or pDNA at all (lane “704 binary”). 
 
a 
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Figure 3.2-1 Agarose gel retardation assay of ternary complexes and binary counterparts. (a) mRNA 
condensation studies using ternary complexes comprising different peptides at various N/P ratios. Binary 
complex consisting of mRNA and T704 at the same concentration served as a binary control. Naked mRNA was 
used as a positive control (+), with NF-water as the negative control (-). (b) pDNA condensation studies using 
ternary complexes comprising different peptides at various N/P ratios. Binary complex consisting of pDNA and 
T704 at the same concentration served as binary control. 1kb DNA standard was used as a reference (1kb), 
naked pDNA was used as a positive control (+) with NF-water as the negative control (-).  
 
3.2.2 Dynamic light scattering (DLS) measurements 
We further evaluated and compared the physiochemical properties of binary complexes and 
ternary complexes via DLS measurements. pDNA formed nanoparticles with T704 in an 
average diameter of 206 ± 18 nm (Table 3.2), which was in agreement with previously 
published reports
102,130
. Particles of mRNA/T704 binary complex showed, however, an 
average diameter of 65.2 ± 6.5 nm under the same condition, suggesting mRNA and pDNA 
behave distinctively with respect to polymer binding and complexation. Interestingly, the 
particle size of all T704/peptide/pDNA ternary complexes remarkably declined below 100 nm 
compared with the binary counterpart. Whereas mRNA based ternary complexes just showed 
a slight decrease in nanoparticle size compared with the binary counterpart. The addition of 
peptide component into both mRNA and pDNA based complexes on one hand increased the 
zeta potential of resultant complexes from negative to positive, on the other hand, ternary 
complexes tend to form monodisperse nanoparticles compared with binary counterparts as 
indicated by the polydispersity index (PDI) of each complex in Table 3.2.  
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Table 3.2 The size and zeta potential measurements of T704 based binary and ternary 
complexes containing mRNA or pDNA. 
Complex Particle size (nm) Zeta-potential (mV) PDI 
mRNA + T704 
mRNA + T704 + Peptide 0 (N/P=10) 
65.2 ± 6.5 
55.2 ± 6.3 
-23.0 ± 1.6 
19.3 ± 1.3 
0.449 
0.237 
mRNA + T704 + Peptide 4 (N/P=5) 51.2 ± 5.4 15.8 ± 0.6 0.233 
mRNA + T704 + Peptide 9 (N/P=5) 44.2 ± 4.2 12.8 ± 1.6 0.313 
pDNA + T704 
pDNA + T704 + Peptide 0 (N/P=20) 
206 ± 18.0 
69.8 ± 4.9 
-19.0 ± 2.3 
22.8 ± 0.7 
0.518 
0.324 
pDNA + T704 + Peptide 4 (N/P=5) 68.7 ± 1.8 20.3 ± 0.5 0.238 
pDNA + T704 + Peptide 9 (N/P=5) 59.6 ± 4.6 16.9 ± 2.2 0.276 
All the complexes used in the assay were prepared with the T704 at the ratio of 63 (w/w, relative to nucleic acid) 
and the peptide at the respective N/P ratio indicated in the bracket using methods described in “METHODS”. 
The mRNA or pDNA concentration in all complexes was fixed at 10 µg/ml. 
 
3.2.3 Transmission electron microscopy (TEM) 
The morphology of binary and ternary complexes was investigated by TEM. As shown in 
Figure 3.2-2a, mRNA/T704 binary complex appeared as either individual or clustered 
suborbicular particles with uneven size, some uncomplexed mRNA molecules could also be 
observed (marked with arrows in Figure 3.2-2a). The pDNA/T704 binary complex appeared 
to be of large irregular shape with varying sizes (Figure 3.2-2b). In contrast, both mRNA 
(Figure 3.2-2c) and pDNA (Figure 3.2-2d) based ternary complexes spontaneously self-
assembled into more compact and spherical nanoparticles with a smooth surface. Neither 
uncomplexed nucleic acids nor obvious aggregation could be observed within ternary 
complexes. 
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a   b  
c   d  
Figure 3.2-2 Transmission electron microscopy (TEM) of binary and ternary complexes. (a) TEM 
micrograph of mRNA/T704 binary complex, non-complexed mRNA was marked with arrows. (b) TEM 
micrograph of pDNA/T704 binary complex. (c) TEM micrograph of mRNA-based ternary complex. (d) TEM 
micrograph of pDNA-based ternary complex. The concentration of mRNA or pDNA and T704 in ternary 
complexes was the same with that in binary counterparts. 
 
3.2.4 Stability of ternary complexes 
To examine the vector complex stability, a DNase I protection assay was carried out. pDNA 
based binary and ternary complexes were incubated with 2.5-10 U DNase I for 1 h. 
Remaining pDNA was then extracted from each sample and examined by agarose gel 
electrophoresis (Figure 3.2-3). The gel showed that even the highest concentration of DNase I 
Results 
45 
did not completely degrade pDNA within the ternary complex. In contrast, pDNA within the 
binary complex was completely degraded in the presence of the lowest amount of DNase I 
(2.5 U), which was similar to that of naked pDNA (negative control). 
 
 
Figure 3.2-3 DNase I protection assay. Stability of pDNA-based binary and ternary complexes in the presence 
of increasing DNase I activity. 1kb DNA standard was used as a reference (1kb), naked-pDNA (without DNase I) 
was used as a positive control and (naked-pDNA + 2.5 U DNase I) was used as a negative control. 
 
For the potential clinical application of peptide-poloxamine complexes, the aerosol inhalation 
would be a preferred approach when administering the formulation to the airway of patients, 
rather than the invasive intratracheal instillation with low patient compliance. As a result, it is 
important to see if ternary complexes could resist the shear force created during nebulization 
and whether they remain the activity after nebulization. We evaluated the transfection 
efficiency of non-nebulized and nebulized pDNA/T704/peptide 0 ternary complexes as well 
as pDNA/Lipofectamine2000 lipoplexes. Nebulized lipoplex showed significantly lower 
transfection efficiency compared with the non-nebulized one in both cell lines (p < 0.001), 
whereas the nebulization process did not severely affect the transfection efficiency of 
pDNA/T704/peptide 0 ternary complex (Figure 3.2-4), indicating that peptide-poloxamine 
complexes were more resistant to the shear-force created by jet-nebulizer compared with 
lipid-based formulations. 
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Figure 3.2-4 The influence of nebulization process on the transfection efficiency of pDNA/T704/peptide 0 
ternary complex and Lipofectamine2000 based formulation. "T" means pDNA/T704/peptide 0 ternary 
complex and "L" represents pDNA/Lipofectamine2000 lipoplex. The data are given as the mean ± standard 
deviation (SD) of the mean (n>5). Significant differences are defined as *: p < 0.05; **: p < 0.01; ***: p < 0.005; 
****: p < 0.001; N.S. meant not significant. 
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3.3 Investigations on the underlying mechanism of the 
superior transfection efficiency of ternary complex compared 
with the binary counterpart 
 
To reveal the underlying mechanism of the dramatically enhanced transfection efficiency of 
ternary complex compared with the binary counterpart, the subcellular fate of binary and 
peptide 0 based ternary complex was systemically investigated. 
 
3.3.1 Cellular internalization of binary and ternary complexes 
Flow cytometry was employed to obtain detailed insights into cellular internalization of naked 
fluorescein-labelled pDNA (Fluo-pDNA), binary and ternary complexes containing Fluo-
pDNA in 16HBE cells. The reason we choose 16HBE cells as the model cell line was that 
16HBE cells are more static compared with fast-dividing BEAS-2B cells, thus providing 
huger subcellular barriers and better mimicking in vivo status. As illustrated in Figure 3.3-1, 
binary complex containing Fluo-pDNA was just internalized by less than 0.2 % 16HBE cells 
after 4 h incubation, which was similar to that of naked Fluo-pDNA. In contrast, the ternary 
complex containing Fluo-pDNA successfully entered around 60% of 16HBE cells with a six-
time higher mean fluorescence intensity compared with the binary counterpart.  
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Figure 3.3-1 The cellular uptake of binary and ternary complexes. The uptake of naked fluorescein labelled 
pDNA (Fluo-pDNA), Fluo-pDNA/T704 binary complex, and Fluo-pDNA/T704/peptide 0 ternary complex after 
4 h incubation with 16HBE cells measured by the flow cytometry. 
 
3.3.2 Cellular internalization pathways of ternary complex 
In order to understand the cell entry pathways of ternary complex, the cellular uptake of 
ternary complex was studied in the presence of different inhibitors or at different 
temperatures. As shown in Figure 3.3-2a, either the low temperature (4 ℃) which constrains 
the energy metabolism of cells at a low level or the presence of sodium azide (a metabolic 
inhibitor to deplete ATP), drastically inhibited the cellular uptake of the ternary complex, 
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indicating that their uptake occurred through the energy-dependent endocytosis. To further 
reveal the endocytic pathways of the ternary complex, selective inhibitors of chlorpromazine, 
filipin, protamine, amiloride and sodium chlorate were applied. The cellular uptake of ternary 
complex was partially suppressed by chlorpromazine, a selective inhibitor of clathrin-
mediated endocytosis, but not by filipin, an inhibitor of caveolae-mediated endocytosis 
(Figure 3.3-2b). Both protamine and amiloride significantly inhibited the cellular uptake of 
the ternary complex, indicating that absorptive endocytosis and macropinocytosis which play 
important roles in the uptake process of macromolecules were involved. However, sodium 
chlorate did not influence the internalization process of the ternary complex (Figure 3.3-2b). 
These results suggested that efficient energy-dependent cellular uptake mediated by 
macropinocytosis, electrostatic absorptive endocytosis and clathrin-mediated endocytosis 
could be utilized by the ternary complex. 
 
a  
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Figure 3.3-2 Investigations on the cellular uptake pathways that utilized by the ternary complex. (a) 
Energy-dependent cell uptake of peptide 0 based ternary complex at 4 ℃ and in the presence of NaN3. (b) 
Inhibitory effect of chlorpromazine, filipin, protamine, amiloride and sodium chlorate on the uptake of peptide 0 
based ternary complex. The non-inhibited cellular uptake of peptide 0 based ternary complex was used as the 
control in each assay. Significant differences were defined as *****: p < 0.0001. N.S. meant not significant 
compared with the control. 
 
Additionally, potential receptor-mediated endocytosis was directly examined by the 
competition of excess free peptides. Figure 3.3-3a indicated that free K4R4 peptide 
(KKRRRRKK, the cationic moiety of peptide 0) and free peptide 0 had no influence on the 
cellular uptake of the peptide 0 based ternary complex. This might be due to the fact that 
positively charged peptides did not have specific receptors in the cells and could utilize 
alternative pathways to enhance translocation through the plasma membrane
143
. A similar 
situation could be observed in the case of free lipoic acid and free NLS (Figure 3.3-3a). 
However, the excess amount of free targeting ligand of peptide 9 (GACSERSMNFCG, more 
details in 3.4.2) and free peptide 9 significantly decreased the cellular uptake of the Fluo-
pDNA/T704/peptide 9 ternary complex (Figure 3.3-3b), indicating that the targeting ligand 
played an essential role in mediating the cellular uptake of peptide 9 based ternary complex 
into bronchial epithelial cells. 
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a  
b  
Figure 3.3-3 Investigations on receptor-mediated cellular uptake of the ternary complex. (a) Non-receptor 
mediated endocytosis of peptide 0 based ternary complex, which cannot be inhibited by the excess amount of 
free peptide 0 and its fragment sequence (i.e., NLS, Lipoic acid and K4R4). K4R4 represents the peptide 
KKRRRRKK. The non-inhibited cellular uptake of peptide 0 based ternary complex was used as a control. N.S. 
meant not significant compared with the control. (b) Receptor-mediated cellular uptake of peptide 9 based 
ternary complex, which was significantly inhibited by the excess amount of free peptide 9 and the free ligand S 
(GACSERSMNFCG) which is contained in peptide 9. KWET represents the peptide 
KETWWETWWTEWWTEW which is the hydrophobic moiety of peptide 9. The non-inhibited cellular uptake 
of peptide 9 based ternary complex was used as a control. Significant differences were defined as *****: p < 
0.0001; N.S. meant not significant compared  with the control. 
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3.3.3 Subcellular localization of binary and ternary complexes 
Based on these results, the subcellular location of binary and ternary complexes was further 
investigated by confocal microscopy. The amount of Fluo-pDNA delivered into cells by 
binary complex was very limited and their subcellular location was in a punctate staining 
pattern, indicating that the binary complex was confined within endo/lysosomal compartments 
(Figure 3.3-4). In contrast, plenty of dispersed fluorescence could be observed in the cytosol 
and nucleus of ternary complex transfected cells with the majority of Fluo-pDNA localized 
within the nucleus (Figure 3.3-4). In particular, few of the Fluo-pDNA delivered by ternary 
complex was observed in the endocytic vesicles (Figure 3.3-4, merged), suggesting that 
ternary complex was capable of facilitating efficient endosomal escape which has been 
regarded as the key step “providing the major opportunity to improve gene transfer”144. The 
efficient endosomal escape of ternary complex probably resulted from its distinct cellular 
uptake pathways and/or “proton sponge effect” induced by the cationic moiety within peptide 
component
145
. Once the ternary complex localized in the cytoplasm, the targeting ligand 
(NLS) could exert its function to direct the Fluo-pDNA to the final destination.  
 
Figure 3.3-4 The subcellular location of Fluo-pDNA/T704 binary complex and Fluo-pDNA/T704/peptide 0 
ternary complex after 4 h incubation with 16HBE cells measured by confocal laser scanning microscopy 
(CLSM). Green channel: Fluo-pDNA; Blue channel: nuclei stained by DAPI; Red channel: endocytic vesicles 
marked by LysoTracker
®
 Red DND-99; Merged: the combination of above channels. Scale bar: 10 µm. 
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3.4 Optimizing peptide structure with different candidate 
modules 
 
3.4.1 Each moiety that constitutes the peptide is imperative for the 
activity of peptide in ternary complex 
To prove that those functional moieties within the peptide play pivotal roles in boosting the 
transfection efficiency of ternary complex, we utilized three control peptides to prepare 
ternary complexes and compared their activities in transfecting airway epithelial cells with 
peptide 0 based ternary complexes. Peptide 1 shares the same cationic moiety and targeting 
moiety with peptide 0 but has no anchor moiety. Peptide 2 is a cationic moiety negative 
control of peptide 0 (NLS sequence was simultaneously eliminated from Peptide 2, as there 
are also many basic amino acids in NLS). Peptide 3 shares the same anchor moiety and 
cationic moiety with peptide 0 but contains a mutated NLS targeting sequence in which the 
lysine at position 5 has been replaced by threonine. This mutation is known to be nuclear 
transport deficient
146
. The transfection efficiency of peptide 1, peptide 2 and peptide 3 based 
ternary complexes were optimized (Figure 3.4-2 to 3.4-5) and compared with that of the 
ternary complex containing peptide 0. In terms of pDNA transfection, peptide 1 based ternary 
complex could just reach 7% (in BEAS-2B cells) or half (in 16HBE cells) of the maximum 
signal intensity (on day 3) of peptide 0 counterpart as illustrated in Figure 3.4-1a. 
mRNA/T704/peptide 1 complex showed only one-third of the transfection efficiency of 
mRNA/T704/peptide 0 complex in both BEAS-2B and 16HBE cells (Figure 3.4-1b). 
Interestingly, both pDNA and mRNA based ternary complexes prepared with peptide 2 
displayed a rather low transfection efficiency which was similar to binary counterparts in both 
cell lines (Figure 3.4-1c and 3.4-1d). In the evaluation of the NLS function, pDNA 
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expression from the ternary complex containing peptide 0 was almost 5 times better than the 
counterpart from peptide 3 based ternary complex in BEAS-2B cells (Figure 3.4-1e). 
Although the pDNA expression from peptide 0 based ternary complex and peptide 3 based 
ternary complex were similar on day 2 in 16HBE cells, the former was significantly higher 
than the latter on other days in this cell line (Figure 3.4-1e). 
 
a   
b  
c  
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d  
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Figure 3.4-1 Evaluation of the important roles of functional moieties that constitute peptide 0. The function 
of “anchor moiety” in peptide 0 was proved by comparing the optimum (a) pDNA and (b) mRNA transfection 
efficiency of peptide 0 based ternary complexes with that of peptide 1 based ternary complexes in BEAS-2B and 
16HBE cells. Peptide 1 which did not have hydrophobic “Anchor moiety” was a negative control of peptide 0. 
The function of “cationic moiety” in peptide 0 was studied by comparing the optimum (c) pDNA and (d) mRNA 
transfection efficiency of peptide 0 based ternary complexes with peptide 2 based counterparts in BEAS-2B and 
16HBE cells. Peptide 2 which did not have positively charged amino acids at neutral pH served as a negative 
control of peptide 0. (e) The function of “targeting moiety” (nuclear localization signal, NLS) in peptide 0 was 
evaluated by comparing the optimum pDNA transfection efficiency of peptide 0 based ternary complex with that 
of peptide 3 based ternary complex in BEAS-2B and 16HBE cells. Peptide 3 containing a transport deficient 
NLS was a negative control of peptide 0. Luciferase activity mediated by mRNA transfection was assayed 24 h 
after transfection. Luciferase activity mediated by pDNA transfection was measured on day 1, day 2, day 3 and 
day 4 after transfection. The data are given as the mean ± SD (n>5). Significant differences were defined as *: p 
< 0.05; **: p < 0.01; ***: p < 0.005; ****: p < 0.001; *****: p < 0.0001; N.S. meant not significant. 
 
3.4.2 Optimizing the peptide structure with different candidate 
modules  
Having clarified that how and why peptide 0 was able to mediate efficient transfection of the 
ternary complex, we further evaluated another set of peptides that were composed of different 
candidate modules. Peptide 4 and peptide 5 kept the same anchor moiety and cationic moiety 
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with peptide 0 (same numbers of lysine and arginine in the sequence) but contained different 
targeting moieties. Ligand SERSMNF (ligand S) in peptide 4 and ligand YGLPHKF (ligand 
Y) in peptide 5 were discovered by the phage display and showed high affinity to human 
airway epithelial cells
147
. The receptor of Ligand S is the intercellular adhesion molecule-1, 
because Ligand S closely resembles part of the structure of the receptor binding proteins of 
rhinovirus
148
. The receptor of Ligand Y is currently unknown but Ligand Y displays close 
similarity to a targeting protein within the pathogen Legionella pneumophila
149
. The function 
of the amino acids sequence “GAC…CG” is to provide the ligand component with better 
conformational stability
150
. Peptide 6 and peptide 7 shared a similar structure with peptide 4 
and peptide 5 but differed in the cationic moiety. Unlike the cationic moiety of peptide 4 and 
peptide 5 wherein lysine outnumbered arginine, the cationic moiety of peptide 6 and peptide 7 
contained more arginine than lysine. Peptide 8 had same anchor moiety and targeting moiety 
with peptide 4 but contained a cationic moiety dominated by histidine. Peptide 9, peptide 10, 
peptide 11 and peptide 12 were derived from peptide 4 by substitution of different anchor 
moieties, while peptide 10 comprised a shortened cationic moiety. The optimum composition 
of ternary complexes comprising peptide 4 to peptide 12 showing maximum transfection 
efficiencies was first identified (Figure 3.4-2 to Figure 3.4-5).  
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Figure 3.4-2 Transfection efficiency of mRNA based ternary complexes (comprising different peptides) in 
BEAS-2B cells. Peptide 1 to peptide 12 at different N/P ratios (as peptide 2 did not contain positively amino 
acids at neutral pH, peptide 2 was applied with the same molar concentration of peptide 0 accordingly) were 
complexed with T704 at the concentration of 63 (w/w) respectively, then followed by adding MetLuc-mRNA 
(400ng/well). Luciferase activity was measured 24 h after transfection and was expressed in RLU. Data represent 
the mean ± SD (n>5). 
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Figure 3.4-3 Transfection efficiency of mRNA based ternary complexes (comprising different peptides) in 
16HBE cells. Peptide 1 to peptide 12 at different N/P ratios (peptide 2 was applied with the same molar 
concentration of peptide 0 accordingly) were complexed with T704 at the concentration of 63 (w/w) 
respectively, then followed by adding MetLuc-mRNA (400ng/well). Luciferase activity was measured 24 h after 
transfection and was expressed in RLU. The data are given as the mean ± SD (n>5). 
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Figure 3.4-4 Transfection efficiency of pDNA based ternary complexes (comprising different peptides) in 
BEAS-2B cells. Peptide 1 to peptide 12 at different N/P ratios (as peptide 2 did not contain positively amino 
acids at neutral pH, peptide 2 was applied with the same molar concentration of peptide 0 accordingly) were 
complexed with T704 at concentration of 50 (w/w) respectively, then followed by adding MetLuc-pDNA 
(400ng/well). The same transfection procedure as described above was applied. Luciferase activity was 
measured 24 h, 48 h, 72 h and 96 h after transfection and was expressed in RLU. The data are given as the mean 
± SD (n>5). 
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Figure 3.4-5 Transfection efficiency of pDNA based ternary complexes (comprising different peptides) in 
16HBE cells. Peptide 1 to peptide 12 at different N/P ratios (as peptide 2 did not contain positively amino acids 
at neutral pH, peptide 2 was applied with the same molar concentration of peptide 0 accordingly) were 
complexed with T704 at the concentration of 63 (w/w) respectively, then followed by adding MetLuc-pDNA 
(400ng/well). The same transfection procedure as described above was applied. Luciferase activity was 
measured 24 h, 48 h, 72 h and 96 h after transfection and was expressed in RLU. The data are given as the mean 
± SD (n>5). 
 
The comparison of pDNA or mRNA transfection efficiency mediated by ternary complexes 
comprising these peptides in optimum conditions was displayed in Figure 3.4-6. As 
illustrated in Figure 3.4-6a, pDNA expression from peptide 4, peptide 5 and peptide 7 based 
ternary complexes was similar (peptide 5 and peptide 7 were slightly better at day 3) to that 
from peptide 0 based ternary complexes in BEAS-2B cells. In contrast, peptide 9 based 
ternary complexes showed the highest transfection efficiency from day 1 to day 4 among all 
the tested groups in this cell line. For the transfection of 16HBE cells, both 
pDNA/T704/peptide 6 and pDNA/T704/peptide 9 ternary complexes showed overwhelming 
signals at each time point compared with other counterparts (Figure 3.4-6a). In terms of 
mRNA transfection, peptide 9 based ternary complex was more efficient than other 
counterparts in both BEAS-2B and 16HBE cells (Figure 3.4-6b). These results revealed that 
peptide 9 was the most promising peptide candidate in all aspects. Based on these results, 
peptide 9 based ternary complexes were selected as leading candidates for the following 
studies. 
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Figure 3.4-6 Comparisons of the transfection efficiency mediated by ternary complexes comprising 
different peptides in the optimum composition. (a) MetLuc-pDNA expression in BEAS-2B cells and 16HBE 
cells mediated by ternary complexes containing different peptides. Luciferase activity was measured on day 1, 
day 2, day 3 and day 4 after transfection.  The concentration of T704 in ternary complexes treated for BEAS-2B 
cells was 50 (w/w), and which for 16HBE cells was 63 (w/w); (b) MetLuc-mRNA expression in BEAS-2B cells 
and 16HBE cells mediated by ternary complexes containing different peptides. Luciferase activity was assayed 
24 h after transfection. The concentration of T704 in ternary complexes fixed at 63 (w/w). Data represent the 
mean ± SD (n>5). 
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3.5 Comparisons between the ternary complexes and other 
nonviral transfection reagents 
 
In this chapter, we evaluated and compared the transfection efficiency of the ternary complex 
with other excellent nonviral transfection reagents using luciferase and enhanced green 
fluorescent protein (EGFP) as reporters. Lipofectamine2000 is a well-known commercial 
available reagent that has been commonly used as a standard for in vitro nucleic acid 
transfection in a wide variety of cells. In a previous study, we found Lipofectamine2000 was 
very efficient in the delivery of mRNA into cultured airway epithelial cells
139
. As a result, 
Lipofectamine2000 was used as a lipoplex (complex formed by lipids and nucleic acids) 
control in the current study. Branched polyethyleneimine (brPEI, 25kDa) is a widely-used 
cationic polymer that is regarded as the “gold-standard” for nucleic acid delivery in the past 
few decades and was used as polyplex (complex formed by polymers and nucleic acids) 
control in current study
151
. 
 
3.5.1 In vitro luciferase expression mediated by different carrier 
systems 
We first identified the optimal composition of Lipofectamine2000 lipoplex and brPEI 
polyplex showing maximum transfection efficiency in airway epithelia (Supplementary 
Figure 1 and Supplementary Figure 2), then compared with that of peptide 9 based ternary 
complex. As shown in Figure 3.5-1a, MetLuc-pDNA expression in ternary complex and 
Lipofectamine2000 lipoplex were at the same level in BEAS-2B cells, whereas the luciferase 
expression on day 3 and day 4 mediated by ternary complex was significantly higher than that 
mediated by Lipofectamine2000 in 16HBE cells. Furthermore, ternary complex brought about 
more than 5-times higher (in BEAS-2B cells) or 7-times better (in 16HBE cells) pDNA 
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transfection than brPEI counterparts (Figure 3.5-1a). In contrast, mRNA based ternary 
complex was less efficient than Lipofectamine2000 lipoplex in both cell lines (Figure 3.5-
1b). Compared with brPEI polyplex, mRNA expression induced by ternary complex was 10-
times in BEAS-2B cells and 36-times in 16HBE cells as efficient as that mediated by brPEI 
polyplex (Figure 3.5-1b). These results demonstrated that ternary complex was more efficient 
in delivering pDNA into cultured epithelial cells compared with the lipoplex and polyplex 
controls, while mRNA expression mediated by ternary complex was lower than that mediated 
by the lipoplex control. 
 
a  
b  
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Figure 3.5-1 Comparisons of the in vitro transfection efficiency mediated by ternary complexes (T704 + 
Peptide 9 + pDNA or mRNA) and other nonviral vectors. (a) Optimum MetLuc-pDNA expression mediated 
by ternary complex, Lipofectamine2000 lipoplex and brPEI polyplex in BEAS-2B and 16HBE cells. Luciferase 
activity was measured on day 1, day 2, day 3 and day 4 after transfection. (b) MetLuc-mRNA expression (24 h 
after transfection) mediated by ternary complex, Lipofectamine2000 lipoplex and brPEI polyplex in BEAS-2B 
and 16HBE cells. All formulations were prepared at the optimum ratio to ensure their optimum performance on 
each cell line. The results represent the mean ± SD of three independent experiments. Significant differences 
were defined as *: p < 0.05; **: p < 0.01; ***: p < 0.005; ****: p < 0.001; *****: p < 0.0001; N. S. meant not 
significant. 
 
3.5.2 In vitro enhanced green fluorescent protein (EGFP) expression 
mediated by different carrier systems 
Apart from the evaluation of the total levels of protein production, we also investigated the 
numbers of transfected cells using above-mentioned transfection reagents. BEAS-2B and 
16HBE cells were transfected with mRNA or pDNA encoding EGFP. To visualize EGFP-
mRNA transfected cells, fluorescent microscope pictures were acquired (Figure 3.5-2). 
Results revealed that the transfection efficiency of ternary complexes comprising peptide 9 
was much better than that achieved with brPEI-based formulation and similar to the one 
achieved with Lipofectamine2000 counterpart.  
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Figure 3.5-2 EGFP-mRNA expression mediated by different formulations. Representative expression of 
EGFP-mRNA mediated by ternary complex, Lipofectamine2000 based lipoplex and brPEI based polyplex in (a) 
BEAS-2B cells and (b) 16HBE cells determined by fluorescent microscope. 
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Afterward, the number of EGFP-mRNA or -pDNA transfected cells was quantitatively 
calculated by flow cytometry. As illustrated in Figure 3.5-3, EGFP-mRNA successfully 
expressed in 40.3% ± 4% and 29.2% ± 3% of BEAS-2B cells transfected by 
Lipofectamine2000 lipoplex and ternary complex respectively, whereas only 4.0% ± 2% of 
BEAS-2B cells showed signals in brPEI group. Notably, the fluorescence intensity of ternary 
complex group was comparable to that of Lipofectamine2000 group. A similar profile could 
be observed in EGFP-mRNA transfected 16HBE cells wherein 42.5% ± 3%, 25.8% ± 5% and 
1.9% ± 1% cells were transfected by Lipofectamine 2000 lipoplex, ternary complex and brPEI 
polyplex, respectively (Figure 3.5-3). In terms of EGFP-pDNA transfection, the rate of 
successfully transfected cells was significantly lower than that of EGFP-mRNA transfected 
counterpart, only 10%-20% BEAS-2B or 16HBE cells were successfully transfected by 
ternary complex and Lipofectamine2000 lipoplex (Figure 3.5-3). The culprit for this 
phenomenon would be the barrier posed by the nuclear membrane which is insurmountable 
for pDNA expression but irrelevant for mRNA expression
141
. However, the fluorescence 
intensity (per cell) expressed from EGFP-pDNA transfected cells was at a similar level with 
that expressed from EGFP-mRNA transfected counterparts. The number of EGFP-pDNA 
successfully transfected cells mediated by ternary complex was comparable to that mediated 
by Lipofecamine2000 lipoplex but was significantly higher than that mediated by brPEI 
polyplex in BEAS-2B and 16HBE cells (Figure 3.5-3).   
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Figure 3.5-3 Quantitative investigations on the EGFP positive cells and their mean fluorescence intensity 
in EGFP-mRNA or EGFP-pDNA based formulations transfected BEAS-2B and 16HBE cells via flow 
cytometry analysis. Bars represent the rate of EGFP-positive cells (grey-mRNA, white-pDNA), individual dots 
refer to the mean fluorescence intensity per cell. 
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3.6 Cytotoxicity 
3.6.1 Cytotoxicity of formulations based on ternary complexes, 
Lipofectamine2000 lipoplex and brPEI polyplex in the optimum 
composition 
The potential of the ternary complex for therapeutic purposes can be appropriately interpreted 
only if impending toxic effects are taken into account. As a result, the cytotoxicity of the 
ternary complex (prepared under conditions showing highest transgene expression) was 
investigated and compared with Lipofectamine2000-based and brPEI-based counterparts. As 
shown in Figure 3.6-1, both BEAS-2B and 16HBE cells transfected by ternary complex 
survived most among all the groups. Similarly, brPEI polyplex induced mild toxicity to both 
cell lines. However, severe toxicity was observed in Lipofectamine2000 groups, which 
resulted in as much as 50%-70% cell death.  
 
 
Figure 3.6-1 The cytotoxicity of pDNA based ternary complex, Lipofectamine2000 based lipoplex and 
brPEI based polyplex. BEAS-2B and 16HBE cells were incubated with above formulations for 4 h at 37 ℃ in a 
humidified atmosphere, then fresh cell culture media as recommended were added to substitute above samples. 
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An MTT assay was performed 24 h post transfection. The data are given as the mean ± SD (n>5). Significant 
differences were defined as ***: p < 0.005; ****: p < 0.001; 
 
3.6.2 Cytotoxicity of T704, peptide 9, Lipofectamine2000 and brPEI  
The cytotoxicity of above formulations could be explained when the cytotoxic effect induced 
by T704, peptide 9, Lipofectamine2000 and brPEI alone in a wide concentration range 
(normalized to the weight of dosing per well) was revealed. The half maximal inhibitory 
concentration (IC50) of each candidate in both cell lines was in the following order: 
IC50(Lipofectamine2000) < IC50(brPEI) < IC50(peptide 9) < IC50(T704), implying that the 
components of the ternary complex were safe and well-tolerated materials (Figure 3.6-2).  
 
 
Figure 3.6-2 The cytotoxicity of T704, peptide 9, Lipofectamine2000 and brPEI at different concentrations 
(normalized to µg/well). BEAS-2B cells and 16HBE cells were incubated with different concentrations of 
peptide 9 (0.5 to 40 µg/well), T704 (0.5 to 40 µg/well), Lipofectamine2000 (0.1 to 5 µg/well) and brPEI (0.1 to 
20 µg/well) for 4 h at 37 ℃ in a humidified atmosphere, then fresh cell culture media as recommended were 
added to substitute above samples. An MTT assay was performed 24 h post transfection. The data are given as 
the mean ± SD (n>5). 
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3.7 In vivo evaluation of ternary complexes 
3.7.1 In vivo mRNA expression mediated by ternary complex 
For in vivo evaluation of ternary complexes, we first investigated the mRNA delivery 
efficiency via the intratracheal application. We used in vivo bioluminescence imaging to 
compare the transgene expression induced by intratracheal dosing of following fLUC-mRNA 
based formulations in the lungs of mice: 1) T704-based binary complex in Tyrode’s solution; 
2) Peptide 9/T704-based ternary complex in NF-water; 3) NF-water served as a negative 
control formulation. 24 h post transfection, the luciferase expression was measured. 
Bioluminescence signals were generally too weak to be detected in live mice. Lungs were 
excised from mice to detect the luciferase expression by bioluminescence imaging (Figure 
3.7-1a). Quantitative analysis of the data was performed by drawing regions of interest around 
the area displaying signals in the lungs, and the intensity of the signal in these regions was 
calculated. Using this method of quantification, signals from excised lungs indicated that 
mRNA expression mediated by Peptide 9/T704-based ternary complex was significantly 
higher than that mediated by the binary counterpart (Figure 3.7-1b).  
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Figure 3.7-1 In vivo evaluation of mRNA transfection efficiency mediated by the ternary complex. (a) 
Transgene expression in the lungs of mice (24 h post transfection) following fLUC-mRNA transfections 
mediated by T704-based binary and ternary complex, (b) with a quantitative comparison of their signal 
intensities. Mice treated with NF-water served as negative controls. The lungs were excised prior to 
bioluminescence imaging. Significant differences were defined as * = p < 0.05; 
 
a 
b 
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3.7.2 In vivo evaluation of pDNA transfection efficiency mediated by 
ternary complex 
The ternary complex has shown its superiority in the delivery of pDNA into cultured cells 
compared with other prominent transfection reagents as described above. In order to further 
prove its promising in in vivo applications, in vivo bioluminescence imaging was applied to 
compare the transgene expression induced by intratracheal dosing of following pGM206-
fLUC-CFTR/T2 based formulations in CF-mice: 1) T704-based binary complex in Tyrode’s 
solution; 2) T704- peptide 9 based ternary complex in NF-water; 3) Cationic lipids (DOTAP) 
based lipoplex. DOTAP was chosen as a lipoplex control because it is highly efficient for 
pDNA transfection and has been successfully used for several in vivo applications
152–154
. 
Meanwhile, NF-water served as a negative control formulation. The expression of luciferase 
reporter gene obtained 48 h after intratracheal administration of above-mentioned 
formulations is presented in Figure 3.7-2a. Apart from NF-water group, discrete spots of 
signals are present in the area of lungs of mice. Similar to the previous report
130
, T704 based 
binary complex led to brighter signals compared with that of DOTAP based lipoplex. Mice 
transfected by ternary complex showed the strongest signals among all the groups (Figure 
3.7-2a). It is worth noting that the area expressing signals in the ternary complex group was 
more expanded and dispersed than that of the binary complex group. The epithelium targeting 
ligand which presents in the ternary complex may explain this phenomenon. Statistical 
analysis of the bioluminescence intensity showed that a highly significant difference in 
luciferase expression induced by ternary complex versus binary complex or DOTAP-based 
lipoplexes (Figure 3.7-2b). Transgene expression with ternary complex was nearly doubled 
than that with the binary complex.    
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Figure 3.7-2 In vivo evaluation of pDNA transfection efficiency of the ternary complex. (a) 
Bioluminescence imaging (48 h after transfection) of pGM206-fLUC-CFTR/T2 expression mediated by DOTAP 
based lipoplex, T704 based binary and ternary complex in live mice. Mice treated with NF-water served as 
negative controls. (b) The signal intensity from each sample was measured and quantitatively compared. 
Significant differences were defined as ***: p < 0.005; ****: p < 0.001; 
 
3.7.3 In vivo toxicity of ternary complex 
To study in vivo toxicity and inflammation, pathohistological analysis of lung sections from 
mice treated with NF-water, DOTAP based lipoplex, binary and ternary complexes was 
performed. Lungs of mice treated with NF-water showed no signs of interstitial edema or 
cellular infiltration, and similar histology was observed in mice that were treated with binary 
complex and ternary complex (Figure 3.7-3). In contrast, lungs of mice that received DOTAP 
based lipoplex exhibited thickened alveolar walls and patchy inflammation which was 
predominantly of a macrophage/monocyte nature (Figure 3.7-3b). The trachea sections of 
mice treated with the binary complex and the ternary complex also showed no signs of 
inflammation (Figure 3.7-4).  
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Figure 3.7-3 In vivo toxicity of different formulations. Histopathologic analysis of lung sections from (a) NF-
water, (b) DOTAP-based lipoplex, (c) binary and (d) ternary complex treated mice obtained 48 h after dosing. 
Haematoxylin-Eosin (H&E) staining, × 20 magnification. 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
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Figure 3.7-4 Representative histopathologic analysis of trachea sections. Samples were obtained from mice 
treated with NF-water, T704 based binary and ternary complex 48 h after dosing. Haematoxylin-Eosin (H&E) 
staining, ×40 magnification. 
Binary complex   
Control 
Ternary complex   
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3.8 In vivo long-term transgene expression mediated by 
ternary complexes containing SleepingBeauty (SB) transposon 
system  
3.8.1 In vivo long-term luciferase expression  
To determine if ternary complex could mediate in vivo long-term transgene expression, 
pGM206-fLUC-CFTR/T2 and SB100X-mRNA were formulated and administered to mice 
intratracheally. Two days after dosing, pGM206-fLUC-CFTR/T2 treated and (pGM206-
fLUC-CFTR/T2+SB100X-mRNA) co-transfected mice showed strong luciferase expression 
in the area of lungs (Figure 3.8-1). Only a background-level signal could be observed in 
SB100X-mRNA treated mice in the whole study (Figure 3.8-1). The luciferase expression in 
(pGM206-fLUC-CFTR/T2+SB100X-mRNA) co-treated mice varied between 30-61% relative 
to day 2 in the following investigated periods, whereas the luciferase signal from pGM206-
fLUC-CFTR/T2 treated mice was hardly detectable since 2 weeks post transfection (Figure 
3.8-1). At the pre-determined end (7 weeks) of this investigation, strong bioluminescence 
signals still could be observed in the excised lungs of (pGM206-fLUC-CFTR/T2+SB100X-
mRNA) co-treated group, while lungs from other groups showed no signal (Figure 3.8-1). 
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Figure 3.8-1 In vivo stable and long-term luciferase expression mediated by the ternary complex 
containing SB transposon system. Exemplary bioluminescence images were taken at indicated time points after 
dosing. Mice treated with a single formulation containing SB100X mRNA or fLUC-CFTR/T2 pDNA were 
applied as controls.  
 
  
3.8.2 In vivo long-term CFTR expression  
In order to confirm if there was long-term expression of CFTR in above (pGM206-fLUC-
CFTR/T2+SB100X-mRNA) co-transfected group, CFTR immune-staining study was 
performed and revealed a clear and consistent CFTR expression at the apical side of the 
superficial epithelium of bronchial airways, which was similar to the CFTR signal observed in 
wildtype (WT) group, while only residual CFTR expression (~10%
155
) was observed in the 
sample from untreated CF mice (Fig.3.8-2).  
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Figure 3.8-2 In vivo long-term CFTR expression. Restored long-term (7 weeks after dosing) CFTR expression 
in the bronchial epithelium of mice treated with the ternary complex containing SB transposon system detected 
by histochemical staining assay. The lung sections from untreated CF mice and wildtype (WT) mice were used 
as the negative and positive control, respectively. Scale bar: 10 µm. 
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3.9 Preliminary evaluation of ternary complexes comprising 
other poloxamines or poloxamers  
 
After establishing and optimizing peptide-T704 ternary complexes, it is interesting to 
determine if “ternary complex” strategy endowed by synthetic peptides could generalize to 
other poloxamines or poloxamers. To this end, poloxamine304 (T304), poloxamine904 
(T904), poloxamine90R4 (T90R4) and poloxamer184 (L64) were employed to form ternary 
complexes with synthetic peptides and MetLuc-mRNA. Their transfection efficiency in 
16HBE cells was evaluated. In order to standardize the transfection procedure, we fixed the 
following parameters for all transfections: i) the concentration of mRNA in ternary complex 
was fixed at 400 ng/well (relative to 96-well plates); ii) ternary complex was prepared by first 
mixing equal volume of poloxamine or poloxamer and peptide stock solution, followed by 
adding equal volume of mRNA stock solution; iii) ternary complex was consistently prepared 
in NF-water; iv) ternary complex was incubated with 16HBE cells for 4 h. Similar to T704 
based binary complex, mRNA expression mediated by binary complexes comprising T304, 
T904, T90R4 or L64 were at the background level (Data not shown). 
 
3.9.1 In vitro evaluation of ternary complexes consisting of T304 
3.9.1.1 The influence of T304 concentration within ternary complex 
In order to find out the optimum concentration of T304 within the ternary complex, we started 
from peptide 6 at the N/P ratio of 5 to investigate the influence of T304 concentration on the 
transfect efficiency of mRNA/T304/peptide 6 ternary complexes. As shown in Figure 3.9-1, 
ternary complexes showed a background level of transfection when T304 in the concentration 
range of 10-100 (w/w). The mRNA expression increased with the concentration of T304 from 
250 (w/w), reaching maximum when the concentration of T304 was at 2045 (w/w). Then the 
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mRNA expression remained in the plateau at the higher T304 concentration (2045-2500 
(w/w)). 
 
 
Figure 3.9-1 In vitro transfection efficiency of MetLuc-mRNA/peptide 6/T304 ternary complexes 
comprising T304 at different concentrations. T304 in the concentration range of 10-2500 (w/w, relative to 
mRNA) were complexed with peptide 6 at N/P ratio of 5 and MetLuc-mRNA. The same transfection procedure 
as described in the peptide-T704 ternary complex was applied. Luciferase activity was expressed in RLU. The 
data are given as the mean ± SD (n >5). 
 
3.9.1.2 The influence of peptide component within T304 based ternary complex 
To further optimize T304 based ternary complex, T304 at the concentration of 2000 (w/w) 
were used to formulate ternary complex with mRNA and different peptides at various N/P 
ratios. The transfection efficiency of resulting ternary complexes was displayed in Figure 3.9-
2. The comparison of mRNA expression mediated by ternary complexes in the optimum 
composition was displayed in Figure 3.9-3. Peptide 0, Peptide 6, peptide 7 and peptide 8 
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based ternary complex showed a high level of mRNA expression among all the groups, with 
peptide 0-T304 ternary complex being the most potent one. 
 
 
 
 
Figure 3.9-2 In vitro transfection efficiency of MetLuc-mRNA-T304 based ternary complexes comprising 
different peptides in 16HBE cells. Peptide0, Peptide 6 to peptide 12 at various N/P ratios were complexed with 
T304 at a concentration of 2000 (w/w) and MetLuc-mRNA. Luciferase activity was expressed in RLU. The data 
are given as the mean ± SD (n >5). 
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Figure 3.9-3 Comparisons of the optimum in vitro transfection efficiency mediated by MetLuc-mRNA-
T304 based ternary complexes comprising different peptides in 16HBE cells. The concentration of T304 in 
ternary complexes was 2000 (w/w). The N/P ratio of the peptide in certain ternary complexes was as following: 
peptide12 at 30; peptide 8 at 15; peptide 9 at 10; peptide 0 at 7.5; peptide 6, 10 and 11 at 5; peptide7 at 2.5. 
Luciferase activity was expressed in RLU. The data are given as the mean ± SD (n >5). 
 
3.9.2 In vitro evaluation of T904 based ternary complexes  
3.9.2.1 The influence of T904 concentration within ternary complex 
To evaluate peptide-T904 ternary complex, we used peptide 6 at the N/P ratio of 5 to form the 
ternary complex with T904. As shown in Figure 3.9-4, the mRNA expression mediated by 
T904 based ternary complex showed its maximum expression when the concentration of T904 
was 100 (w/w), which was similar to that of T704 based ternary complexes. Then the mRNA 
expression gradually declined at higher T904 concentration, reaching a plateau since the T904 
concentration was above 350 (w/w).  
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Figure 3.9-4 In vitro transfection efficiency of MetLuc-mRNA/peptide 6/T904 ternary complexes 
comprising T904 at different concentrations. T904 in the concentration range of 25-2500 (w/w, relative to 
mRNA) were complexed with peptide 6 at N/P ratio of 5 and MetLuc-mRNA. Luciferase activity was expressed 
in RLU. The data are given as the mean ± SD (n >5). 
 
3.9.2.2 The influence of peptide component within T904 based ternary complex 
To further optimize T904 based ternary complex, T904 at the concentration of 100 (w/w) was 
used to formulate ternary complex with mRNA and different peptides at various N/P ratios. 
The transfection efficiency of resulting ternary complexes was displayed in Figure 3.9-5.  
 
The comparison of mRNA expression mediated by ternary complexes in optimum 
composition was displayed in Figure 3.9-6. Similar to T704 based ternary complexes, peptide 
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0, peptide 6, peptide 7 and peptide 9 based ternary complexes showed a high level of mRNA 
expression among all the groups, with peptide 9-T904 ternary complex being the highest one. 
 
 
 
Figure 3.9-5 In vitro transfection efficiency of MetLuc-mRNA-T904 based ternary complexes comprising 
different peptides in 16HBE cells. Peptide0, Peptide 6 to peptide 12 at various N/P ratios were complexed with 
T904 at a concentration of 100 (w/w) and MetLuc-mRNA. Luciferase activity was expressed in RLU. The data 
are given as the mean ± SD (n >5). 
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Figure 3.9-6 Comparisons of the optimum in vitro transfection efficiency mediated by MetLuc-
mRNA/T904 based ternary complexes comprising different peptides in 16HBE cells. The concentration of 
T904 in ternary complexes was 100 (w/w). The N/P ratio of the peptide in certain ternary complexes was as 
following: peptide 8 at 40; peptide 12 at 15; peptide 0 at 10; peptide 6, 9 and 11 at 5; peptide 7 and 10 at 2.5. 
Luciferase activity was expressed in RLU. The data are given as the mean ± SD (n >5). 
 
3.9.3 In vitro evaluation of ternary complexes consisting of T90R4 
3.9.3.1 The influence of T90R4 concentration within ternary complex 
T90R4 represents a reverse-sequential poloxamine. In contrast to T904, the ethylenediamine 
molecule first reacted with ethylene oxide (EO) precursors and afterward with propylene 
oxide (PO), leading to tetrafunctional block copolymers displaying poly(propylene oxide) 
(PPO) terminal segments. Peptide 6 at the N/P ratio of 5 was applied to formulate ternary 
complex with T90R4 and mRNA. The mRNA expression mediated by T90R4 based ternary 
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complex progressively raised at low concentration of T90R4 (10-438 (w/w) and drastically 
boosted from T90R4 at the concentration 438 (w/w), reaching the maximum expression at a 
T90R4 concentration of 1636 (w/w) (Figure 3.9-7). Afterward, the mRNA expression 
gradually decreased to half of the maximum when T90R4 was at the concentration of 2500 
(w/w).  
 
 
Figure 3.9-7 In vitro transfection efficiency of MetLuc-mRNA/peptide 6/T90R4 ternary complexes 
comprising T90R4 at different concentrations. T90R4 in the concentration range of 10-2500 (w/w, relative to 
mRNA) were complexed with peptide 6 at N/P ratio of 5 and MetLuc-mRNA. Luciferase activity was expressed 
in RLU. The data are given as the mean ± SD (n >5). 
 
3.9.3.2 The influence of peptide component within T90R4 based ternary complex 
To further investigate the influence of peptide component towards the transfection efficiency 
of T90R4 based ternary complex, T90R4 was fixed at the concentration of 1600 (w/w) to 
form ternary complexes with mRNA and different peptides at various N/P ratios. The 
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transfection efficiency of resulting ternary complexes was displayed in Figure 3.9-8. The 
maximum mRNA expression mediated by ternary complexes containing different peptides 
was compared (Figure 3.9-9). The results showed that peptide 0, peptide 6, peptide 7 and 
peptide 8 based ternary complex were potent candidates, with peptide 7-T90R4 ternary 
complex being the most efficient one. 
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Figure 3.9-8 In vitro transfection efficiency of MetLuc-mRNA/T90R4 based ternary complexes comprising 
different peptides in 16HBE cells. Peptide0, Peptide 6 to peptide 12 at various N/P ratios were complexed with 
T90R4 at a concentration of 1600 (w/w) and MetLuc-mRNA. Luciferase activity was expressed in RLU. The 
data are given as the mean ± SD (n >5). 
 
 
  
 
Figure 3.9-9 Comparisons of the optimum in vitro transfection efficiency mediated by MetLuc-
mRNA/T90R4 based ternary complexes comprising different peptides in 16HBE cells. The concentration of 
T90R4 in ternary complexes was 1600 (w/w). The N/P ratio of the peptides in certain ternary complexes was as 
following: peptide 12 at 30; peptide 8 at 10; peptide 0 and 10 at 7.5; peptide 6, 9 and 11 at 5; peptide 7 at 2.5. 
Luciferase activity was expressed in RLU. The data are given as the mean ± SD (n >5). 
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3.9.4 In vitro evaluation of ternary complexes consisting of L64 
3.9.4.1 The influence of L64 concentration within ternary complex 
Poloxamer based block copolymers, consisting of EO and PO blocks arranged in a linear 
triblock structure (EOx-POy-EOx), are biocompatible amphiphilic copolymers which have 
been approved by FDA for the use of in vivo drug delivery
156
. Poloxamer based block 
copolymers are recognized pharmaceutical excipients listed in the US and British 
Pharmacopoeia. Poloxamers have proven to be useful gene transfer vehicles in many in vivo 
studies. Poloxamer184 (L64) is one of the frequently used candidates within this chemical 
family. To evaluate peptide-L64 ternary complex, peptide 6 at the N/P ratio of 5 were 
formulated with MetLuc-mRNA and L64 in the concentration range of 50-2500 (w/w). The 
mRNA expression showed a sharp growth with the increased concentration of L64, reaching 
maximum at the concentration of 300 (w/w) (Figure 3.9-10). A descent of mRNA expression 
could be observed when the concentration of L64 within the ternary complex was above 400 
(w/w) (Figure 3.9-10). This decline of mRNA expression may result from cytotoxic effects of 
highly concentrated materials. As revealed by the MTT assay, more than half of the cells were 
dead when the concentration of L64 within the ternary complex was above 500 (w/w) (data 
not shown). 
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Figure 3.9-10 In vitro transfection efficiency of MetLuc-mRNA/peptide 6/L64 ternary complexes 
comprising L64 at different concentrations. L64 in the concentration range of 50-2500 (w/w, relative to 
mRNA) were complexed with peptide 6 at N/P ratio of 5 and MetLuc-mRNA. Luciferase activity was expressed 
in RLU. The data are given as the mean ± SD (n >5). 
 
3.9.4.2 The influence of peptide component within L64 based ternary complex 
To further investigate the impact of peptide component towards the transfection efficiency of 
L64 based ternary complex, L64 was fixed at the concentration of 300 (w/w) to form ternary 
complexes with mRNA and different peptides at various N/P ratios. The transfection 
efficiency of resulting ternary complexes was displayed in Figure 3.9-11.  
 
The maximum mRNA expression mediated by ternary complexes containing different 
peptides was compared (Figure 3.9-12). The overall transfection efficiency of poloxamer-
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based ternary complexes was lower than that of poloxamine counterparts. Among all the 
investigated groups, Peptide 0, 7 and 9 based ternary complexes were relatively more potent, 
with peptide 0-L64 ternary complex showing the highest transfection. 
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Figure 3.9-11 In vitro transfection efficiency of MetLuc-mRNA/L64 based ternary complexes comprising 
different peptides in 16HBE cells. Peptide 0, peptide 6 to peptide 12 at various N/P ratios were complexed with 
L64 at a concentration of 300 (w/w) and MetLuc-mRNA. Luciferase activity was expressed in RLU. The data 
are given as the mean ± SD (n >5). 
 
 
Figure 3.9-12 Comparisons of the optimum in vitro transfection efficiency mediated by MetLuc-
mRNA/L64 based ternary complexes comprising different peptides in 16HBE cells. The concentration of 
L64 in ternary complexes was 300 (w/w). The N/P ratio of the peptides in certain ternary complexes was as 
following: peptide 8 at 40; peptide 12 at 20; peptide 9 at 10; peptide 6 and 7 at 7.5; peptide 0 and 11 at 5; peptide 
10 at 2.5. Luciferase activity was expressed in RLU. The data are given as the mean ± SD (n >5). 
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4 DISCUSSION 
Successful gene therapy requires the gene delivery system to efficiently  overcome various 
biochemical and physiological barriers. Therefore, a versatile delivery vehicle is needed to 
achieve efficient and safe nucleic acids delivery. Among various non-viral gene delivery 
systems, peptide-based formulations have gained considerable attention because of the ease of 
synthesis and chemical modification, the versatility of side-chain groups, and biodegradability 
etc.
157
. Nevertheless, there are few reports on the successful in vivo therapeutic nucleic acids 
delivery with peptide-based delivery vectors, which mainly due to the vulnerable and unstable 
properties of these complexes, leaving them therapeutically less potent
158
.  In the majority of 
applications, synthetic peptides were employed to conjugate with lipid or polymer-based 
carriers to formulate hybrid nanoparticles for gene delivery
159,160
. However, the key 
challenges in hybrid nanoparticles development are the multistep syntheses, complicated 
purification, and distinct characterization in numerous steps prior to evaluation of their 
performance, which leads to the low efficiency, tedious chemical synthesis, time 
consumption, and expensiveness
161
. In the current study, we developed a synthetic peptide 
based platform to form compact and homogenized nanoparticles with poloxamine-based 
copolymers. The resulting nanoparticle represents a novel class of gene delivery vehicle 
which is self-assembled via noncovalent interaction between peptide and block copolymer 
component. Such peptide-poloxamine nanoparticle is easy to prepare and could be tailor 
designed for different therapeutic purposes (e.g., targeting to different tissues or organelles). 
The peptide-poloxamine nanoparticle could integrate advantages afforded by peptide and 
poloxamine components while excluding their inherent disadvantages. Considering the fact 
that GMP-grade poloxamine and synthetic peptide are commercially available with low costs, 
the peptide-poloxamine based formulations as a result hold promising in clinical applications. 
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4.1 Establishing and characterization of ternary complexes  
Apart from some important parameters such as the concentration of components, the medium 
used for preparation, transfected cell line and incubation time, we found that the method for 
preparing the peptide-T704 ternary complexes had an enormous impact on gene transfection 
efficiency. While ternary complexes prepared by packing mRNA with T704 first and adding 
peptide component afterward (the “T704 first” method) or condensing mRNA with pre-mixed 
peptide-T704 solution (the “mRNA last” method) showed efficient gene expression, the 
complexes generated by mixing mRNA with peptide first and adding T704 copolymer 
afterward (the “peptide first” method) produced significant lower transgene expression in 
comparison. It is possible that the “T704 first” and the “mRNA last” methods possibly lead to 
the formation of a compact micelle-like structure consisting of a condensed hydrophobic core 
(comprising polypropyleneoxide (PPO) building blocks of T704 and peptide where nucleic 
acid payloads bind) and a hydrophilic shell that is composed of polyethyleneoxide (PEO) 
blocks from T704 with the presence of targeting ligand from peptide. The targeting ligand in 
such nanoparticles could easily take effect. On the other hand, the targeting ligand from the 
synthetic peptide in ternary complexes prepared by the “peptide first” method might have 
been masked by T704 copolymer that was added subsequently, thus resulting in lower 
transfection efficiency. Another possible reason for this phenomenon may result from a 
stronger binding between the peptide component and mRNA molecules prepared by “peptide 
first” method, more details were elaborated in chapter“4.4”. 
  
In addition, the hydrophilic outer corona has important functions in prohibiting nanoparticles 
aggregation and increasing the stability of ternary complexes, this was partially confirmed by 
the colloidal stability studies. All these features of ternary complex help to meet the criteria of 
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efficient inhaled gene vectors which must be small enough to diffuse through the mucus mesh 
while possessing a muco-inert surface to avoid adhesion to mucus constituents
162
. 
 
4.2 Investigations of the underlying mechanism of the superior 
transfection efficiency of ternary complex compared with the 
binary counterpart 
Investigations of the cellular uptake and subcellular location of binary and ternary complexes 
revealed that ternary complex is able to overcome most of the challenges associated with 
successful in vitro gene transfer including the cellular uptake, intracellular transport, 
endosome escape and nucleus import, while none of which could be conquered by the binary 
complex. This would be the reason why binary complex showed background level 
transfection as described above. The seemingly-contradictory facts between efficient in vivo 
gene transfer profile and poor in vitro gene transfer profile of binary complex suggested that 
T704-based copolymers possessed characteristics to conquer various extracellular barriers in 
lung tissue whereas these features probably excluded them from overcoming barriers at 
cellular level, similar to the case of “polyethylenglycol (PEG) modification dilemma”163. On 
the other hand, we can also infer that the in vivo gene expression of binary complex resulted 
from the very low portion of nucleic acid payloads that passively diffused into cells and 
localized to the final target site, emphasizing the huge unexplored spaces existed in the in vivo 
transfection efficiency mediated by T704-based copolymers. 
 
As already shown in many studies, cell-penetrating-peptides, which comprise short peptide 
sequences rich in basic amino acids, could utilize “direct translocation” pathway which is 
independent of energy consumption
164
. Several differences were observed between the 
internalization of unconjugated cell-penetrating-peptides and conjugates that consist of cell-
penetrating-peptides and high molecular-weight molecules ( normally proteins and DNA), 
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suggesting the distinct internalization mechanism utilized by the same peptide, depending on 
the absence or presence of a linked cargo
165
. In terms of peptide 0 in the current study, it 
shares a similar arginine and lysine rich peptide structure with cell-penetrating-peptides. The 
cellular internalization of peptide 0 based ternary complex was completely abolished by low 
temperature (4 ℃), indicating the absence of “direct translocation” pathway in the cellular 
uptake of peptide 0 based ternary complex. Based on this information, it could be inferred that 
the cellular uptake pathway of cell-penetrating-peptides may also be influenced or altered 
when they noncovalently interact with cargo molecules. 
 
4.3 Optimizing peptide structure with different candidate 
modules 
The significantly decreased transfection efficiency of peptide 1, peptide 2 and peptide 3 based 
ternary complexes compared with peptide 0 based ternary complex indicated that anchor 
moiety, cationic moiety and targeting moiety are indispensable to the efficient in vitro 
transfection of ternary complexes. Among all these moieties, the cationic part is particularly 
important. This was in agreement with previous studies which indicate that positive charge in 
the carrier system is not only helpful in condensing nucleic acids payload to avoid nuclease 
degradation but also plays important roles in overcoming various membrane-based 
barriers
166,167
. Heparan sulfate proteoglycans on the cell surface may play an important role in 
the peptide internalization process
168
. On the one hand, the binding of the cationic moiety to 
cell surface proteoglycans could promote the interaction of the synthetic peptide with the 
cellular membranes, facilitating the subsequent interactions necessary to the translocation 
process. On the other hand, the same binding step could lead to certain endocytic mechanism 
which results in the internalization of synthetic peptide. According to a previous study, the 
cellular internalization of the arginine based peptide was shown to be mediated by an 
endocytic mechanism dependent on peptide binding to heparan sulfate proteoglycans
169
. The 
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authors of this study also indicated that the heparan sulfate chains would be degraded by 
heparanase once inside the endosome, leading to dissociation of the peptides and consequent 
interaction of the arginine oligomers with the endosomal membrane, thus promoting its 
endosome escape and subsequent release into the cytoplasm
169
. 
 
In the screening of ternary complexes containing peptide 4 to peptide 12, it is particularly 
interesting to compare peptide 4 and peptide 9. Apart from the same cationic moiety and 
targeting moiety inherited from peptide 4, peptide 9 specifically contained an enlarged 
hydrophobic area made by a quadruple tryptophan-rich sequence in anchor moiety. An 
attractive hypothesis for the superiority of peptide 9 would be that the expanded hydrophobic 
moiety may increase its capacity for docking the PPO groups of T704, thus resulting in a 
more compact and stable structure than other counterparts. This could be partially confirmed 
via size measurement showing that the particle size of peptide 9 based ternary complex was 
slightly smaller than other counterparts (Table 2). Meanwhile, we also evaluated the gene 
transfer ability of peptide 9 (as a single component to form a complex with pDNA). As shown 
in Supplementary Figure 3, peptide 9 alone could just mediate a MetLuc-pDNA expression 
to a level that less than 200000 RLU in both investigated cell lines, which represents less than 
10% of the pDNA expression mediated by peptide9-T704 ternary complex, emphasizing 
again the superiority of ternary complex. In the evaluation of targeting moiety, different 
candidates had their own advantages in different aspects, but ligand S exceeded others in 
transfecting 16HBE cells which better mimic the in vivo status. Another advantage of ligand S 
is that it was completely functional at a rather low concentration compared with NLS, thereby 
decreasing the positive charge and toxicity of ternary complex. It is worth to note that ternary 
complexes formed by peptide 10 which possess “short” cationic moiety were not capable of 
mediating efficient mRNA or pDNA transfection in both cultured cells, highlighting the 
importance of cationic moiety. One possible explanation for this phenomenon is that limited 
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numbers of lysine/arginine might not be sufficient to trigger an efficient intracellular uptake 
and endosome escape of nucleic acid payloads
157
. When comparing the transfection efficiency 
of peptide 4 and peptide 6 based ternary complexes in 16HBE cells, arginine residues were 
more efficient in mediating mRNA and pDNA transfection compared with lysine residues, 
and there seemed to be an optimal number of arginine residues (> 8) for them to be effective 
in the ternary complex.  
 
4.4 Comparison of the transfection efficiency of ternary 
complexes with other nonviral transfection reagents 
Ternary complexes were more efficient compared with 25kDa brPEI polyplexes in all aspects, 
but they were still inferior to Lipofectamine2000 lipoplex in mediating mRNA delivery, this 
is consistent with previous studies implying the superiority of lipid-based carriers compared 
with other nonviral vectors in mRNA delivery81,82. We found this phenomenon did not result 
from the differences between the amount of nucleic acid payloads delivered into cells by these 
carriers, as ternary complex could efficiently mediate the uptake of nucleic acid payloads by 
almost 70% 16HBE cells whereas the Lipofectamine2000 counterpart was internalized by 
only 22% 16HBE cells (Supplementary Figure 3). The binding strength represents a critical 
parameter in mRNA expression because the mRNA molecules should be released from the 
delivery vehicles to facilitate subsequent translation process
170
. We performed a heparan 
sulfate (HS) competition assay to see if there is any difference between the binding strength of 
pDNA within the ternary complex and that of mRNA. As shown in Supplementary Figure 4, 
pDNA could be released from the ternary complex when the HS/pDNA ratio (w/w) reached at 
50, whereas mRNA could not be released from the ternary complex at the same HS/mRNA 
ratio. Only partial mRNA release could be observed in the ternary complex at the highest 
HS/mRNA = 100 (w/w) ratio. Results also showed that mRNA within Lipofectamine2000 
lipoplex could not be retarded (Supplementary Figure 5, lane “mRNA Lipoplex”), revealing 
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the weak affinity between mRNA and Lipofectamine2000. Therefore, one possible reason for 
the inferior mRNA transfection efficiency of the ternary complex compared with that of 
lipoplex most likely resulted from the strong binding between mRNA molecules and the 
cationic moiety of the peptide. Further efforts to improve the transfection efficiency of the 
ternary complex containing mRNA will be focused on the adjustments of the cationic moiety 
of peptide in order to obtain a balance between the affinity to mRNA molecules and ability to 
overcome cellular barriers. 
 
4.5 Cytotoxicity 
The cytotoxicity of peptide-poloxamine nanoparticles is another important parameter for their 
application as nucleic acid delivery vehicles. MTT assay showed that T704 was not cytotoxic 
in vitro at low and moderate concentrations. However, T704 at high concentration may 
destabilize the cell membrane and subsequently induces cell death according to the previous 
investigation
111
. In addition, although showing severe toxicity at high concentration, peptide 9 
is actually rather safe when considering that peptide 9 already exerts its maximal function in 
the ternary complex at a very low concentration (around 2.0 µg/well) at which only negligible 
cytotoxicity could be observed. Degradation of peptides by intracellular trypsin-like protease 
would be one of the reasons accounting for their alleviated cytotoxicity. Trypsin-like protease 
predominantly cleaves the carboxyl side of the arginine and lysine residues within peptide 
sequence
171
, and peptide 9 is composed of multiple lysine and arginine residues. The safety 
profile of peptide-poloxamine nanoparticles was further confirmed in the in vivo application. 
T704 based binary complexes and T704-peptide ternary complexes did not cause 
inflammation in the lungs of CF mice, whereas severe inflammation was observed in the 
lungs of DOTAP lipoplex treated mice. These results are consistent with that observed in the 
previous study
130
. However, there was a study showing that PPO building blocks from 
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poloxamines sometimes elicits mild immunogenic response
172
. As a result, it is important to 
investigate the safe concentration range of poloxamine used for different therapeutic 
applications.   
 
4.6 In vivo long-term restoration of CFTR deficiency 
The most common approach for CF gene therapy relies on the transfer of a functional copy of 
the wildtype CFTR gene into deficient cells so that the channel activity could be corrected. 
The disadvantage of this approach is the transient gene expression profile that is not qualified 
for CF treatment in which repeated dosing is required due to the turnover of slowly dividing 
cells. Recently, genome editing tools have emerged, such as clustered regularly interspaced 
short palindromic repeats associated to Cas9 nucleases (CRISPR/Cas9), transcription 
activator-like effector nucleases and zinc-finger nucleases. These genome correction 
strategies are designed to correct the mutant gene within its original genome with low off-
target effect. However, in terms of CF gene therapy using these genome editing systems, only 
a few preliminary in vitro investigations have been reported up to date
173,174
. The deficiency 
of potent delivery systems critically hindered the in vivo translation process of these genome 
editing systems for CF applications.  
 
An alternative approach has been reported up to date. The approach is mediated by synthetic 
oligonucleotide analogs, namely triplex forming peptide nucleic acids that are able to induce 
DNA repair on the sequence-specific triplex formation at targeted genomic sites
175,176
. 
Intranasal delivery of poly(lactic-coglycolic) acid (PLGA) based nanoparticles containing 
triplex-forming peptide nucleic acids and donor DNA in CF mice induced a response to cyclic 
adenosine monophosphate (cAMP)-stimulated chloride efflux in the nasal epithelium 
potential difference assay
177
, which is a sign of corrected CFTR function. Furthermore, a deep 
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sequencing analysis suggested that a correct gene editing of the Phe508del mutation in ~1 % 
of mouse lung cells was detected
177
.  
 
In the present study, we utilized a SleepingBeauty (SB) transposon system for long-term 
correction of CFTR deficiency. SB transposon system contains two components: (i) a 
transposon element containing a gene-expression cassette and (ii) a genetic element encoding 
SB transposase enzyme which catalyzes the transposition of transposon element from one 
genomic locus to another
178
. When transposing the expression cassette from a plasmid into the 
genome, long-term expression of the gene cassette can be achieved
179
. This system combines 
the advantages of viral vectors (directed integration of single copies of a therapeutic gene) 
with the advantages of nonviral vectors (the absence of protein factors that can elicit adverse 
reactions)
180
. The feasibility of the SB transposon system for in vivo applications was first 
demonstrated by Yant et al. who showed long-term expression of clotting Factor IX in 
clotting Factor IX-deficient hemophilic mice model and of α1-antitrypsin in normal mice181. 
This initial work was followed by the successful treatment of other mouse models of genetic 
disease, including mucopolysaccharidosis (MPS) types I and VII
182,183
, hemophilia A
184–186
 
and inherited tyrosinemia
187
. Apart from that, SB transposons system has also been applied 
for the in vivo treatment of B-cell lymphoma
188–190
, sickle cell anemia
191
, glioblastoma 
multiforme
192
 and epidermolysis bullosa
193
. Moreover, SB transposons system has been 
reported to treat jaundice
194
 and pulmonary hypertension
195
 in the rat model. 
 
Up to date, SB transposon system has been successfully delivery to the liver of mice via 
intravenous route (both by hydrodynamic injection of naked plasmid and by injection of 
plasmid complexed with linear polyethyleneimine) in many investigations. Studies focusing 
on lung as the target tissue of SB transposon system are also available. By intravenous 
injection of SB transposon system complexed with linear polyethyleneimine, Belur et al. 
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demonstrate sustained expression of luciferase transposons in the mouse lung
196
. 
Immunohistochemistry analysis revealed that the majority of the transduced cells were type-2 
alveolar pneumocytes
196
. This is mainly because of vector entrapment in the alveolar 
capillaries of the pulmonary circulation, the first capillary bed encountered after intravenous 
administration
138
. Liu et al. subsequently proved that such expression can be targeted to 
endothelial cells of the lung using the endothelian-1 promoter to regulate transgene expression 
in the SB transposon system
197
. Systemic delivery of SB transposon system is potentially 
advantageous in the treatment of diseases such as cancer, for which both primary and 
metastatic tumors are located deep in the lung. However, if SB transposon system based gene 
therapy for CF is to be effective, genetic payloads have to be targeted to the airway epithelial 
cells which are the primary expression sites of CFTR
198
. 
 
Airway delivery of SB transposon system was first reported by Lawton et al. who intranasally 
administered SB transposon system in liposome complexes to BALB/c mice
199
. Although a 
significantly higher level of luciferase expression could be observed in SB transposon system 
transfected mice compared with the control group (treated with pDNA expressing inactive 
transposase) at 84 days after dosing, integration site analysis within the lung cell genome 
suggested that no integration events could be rescued within samples from SB transposon 
system transfected mice
199
. The authors also revealed that the number of lung epithelial cells 
transfected using this protocol was very low (around 1 in 500000) via parallel studies using 
the EGFP reporter
199
. These results indicated that an improvement in the delivery efficiency 
of SB transposon system to the lung epithelium is required in order to demonstrate SB 
mediated integration in the airway epithelial genome. In a recent study, Cooney et al. 
demonstrated a sustained reporter gene (luciferase) expression after intranasal delivery of 
viral vectors containing piggyBac DNA transposon to mice
200
. They also showed a persistent 
correction of Cl
-
 current in differentiated primary cultures of human airway epithelia derived 
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from CF patients using viral vectors containing piggyBac encoding CFTR
200
. However, the 
authors of this study did not show a long-term correction of CFTR in in vivo conditions, 
which presumably resulted from the viral vector size limitation to integrate an efficient 
piggyBac DNA transposon that is qualified for in vivo applications. Although nonviral 
delivery of transposon system was thought to be inefficient in somatic cells for the in vivo 
therapeutic application of transposon systems
200
, SB-transposon/T704/peptide nanoparticles in 
the current study were able to facilitate long-term restoration of the CFTR deficiency in CF 
mice. However, further investigations in large animal models are still necessary. 
 
It is worth to note that the potential cytotoxicity of transposases needs careful considerations. 
As the transposase providing source has always been a co-delivered DNA molecule in the 
majority of previous SB mediated genome modification studies. Using DNA molecule as the 
transposase-encoding sequence may be problematic and cause unexpected toxicity. Continued 
expression and potential integration of transposase-encoding DNA may lead to transposon re-
mobilization and re-integration, increasing the risk of genotoxicity. On the other hand, it has 
been revealed that SB transposase, including conventional one and the newly developed 
codon-optimized SB100X, may trigger apoptosis and premitotic arrest
201
. So the SB 
transposase itself is toxic to the recipient cells. In the current study, we addressed such 
potential safety concern by using in vitro transcribed messenger RNA (IVT-mRNA) as a 
source of SB transposase
202
. Because of its safe and transient protein expression profile, IVT-
mRNA represents a promising candidate in the development of novel therapeutics for genetic 
diseases, vaccines or genome editing strategies, especially when its inherent shortcomings 
(e.g., instability and immunogenicity) have been partially addressed via structural 
modifications. 
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4.7 Distinct behaviors of ternary complexes comprising 
different poloxamines  
In the evaluation of T704 based ternary complexes comprising different peptides, T704-
peptide 9 ternary complexes mediated the most potent mRNA and pDNA expression from day 
1 to day 4 among all the tested groups in two cell lines of airway epithelia. All these results 
suggested that peptide 9 was the best performing candidate in the formation of  the ternary 
complex with T704. Peptide 9 was also the best candidate for poloxamine904 (T904) based 
ternary complexes, this might result from the fact that T704 and T904 share a similar structure 
and physicochemical property (Figure 1.4-1 and Supplementary Table 1).  However, the 
story was completely different when it comes to the ternary complex comprising other 
poloxamines. When peptide 9 formed the ternary complex with poloxamine304 (T304) or 
poloxamine90R4 (T90R4), the maximum mRNA expression mediated by the resulting T304-
peptide 9 or T90R4-peptide 9 ternary complexes was less than 200000 RLU in 16HBE cells, 
which represented just one fifth of the mRNA expression mediated by T704-peptide 9 ternary 
complex. On the other hand, peptide 8 works surprisingly perfect with T304 and T90R4. 
mRNA/T304/peptide 8 ternary complexes in optimum composition could reach to comparable 
gene transfection with that of mRNA/T704/peptide 9 counterpart. When comparing 
mRNA/T304/peptide 8 and mRNA/T704/peptide 8 ternary complexes, mRNA expression 
mediated by the former was more than 100-fold higher that mediated by the latter. All these 
results indicated that different peptides interact distinctively with different poloxamines. The 
resulting ternary complexes may show completely different transfection profiles. The 
underlying mechanism of this phenomenon probably resulted from distinct interacting 
behaviors between peptides and poloxamines. The resultant ternary complex conformation is 
dependent on i) the proportion and the size of both the PPO and PEO segments within a 
certain poloxamine; as well as on ii) forces including the electrostatic interactions, hydrogen 
bonding and hydrophobic forces between the PPO block in poloxamines and the anchor 
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moieties in peptide; and on iii) nanoparticle-solvent interactions. All these factors determine 
the final structure of the peptide-poloxamine ternary complex and subsequently influence the 
transfection profiles of the resulting peptide-poloxamine ternary complex. 
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5 SUMMARY 
 
In my dissertation, a synthetic peptide-based platform which makes efficient in vitro 
transfection of poloxamine-based block copolymers possible was developed. When 
spontaneously forming compact and homogenized ternary complex with T704 and therapeutic 
nucleic acids via a simple self-assembly, the peptide component can mediate efficient in vitro 
and in vivo gene transfection. mRNA expression mediated by peptide-T704 nanoparticles 
could be drastically increased from the background level to 870000 relative light units which 
is 35-times higher than that mediated by 25kDa brPEI, while pDNA expression was 
dramatically boosted from background level to a level that was comparable with 
Lipofectamine2000 mediated one but with less cytotoxicity. Particularly, the superiority of 
ternary complex compared with the binary counterpart and the lipid-based formulation was 
further validated in CF mice. 
 
The ternary complex holds several unique features that are able to overcome various 
extracellular and intracellular barriers. By preventing non-specific interactions with 
extracellular matrix components, T704 in ternary complex affords the ability to overcome 
biological barriers formed in the lung tissue, enabling ternary complex efficiently penetrated 
the adhesive mucus gel layer through nanoporous to reach the underlying epithelium. 
Subsequently, the synthetic peptide in ternary complex provides the possibility of specific and 
efficient delivery of genetic payloads into the target cell and target organelle, rather than the 
passive diffusion manner of binary counterpart which is similar to that of naked nucleic acids. 
Importantly, the ternary complex demonstrated favorable safety profiles in both in vitro and in 
vivo applications. The biodegradability of synthetic peptides is an additional beneficial factor 
when the repeated dosing is required. By virtue of these advantages, ternary complex is able 
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to efficiently transfect cultured epithelial cells as well as airway epithelia of mice, indicating 
their great potential for pulmonary gene delivery. 
 
Although nonviral delivery of transposon system was previously thought to be inefficient in 
somatic cells for in vivo therapeutic application
200
, SB-transposon/T704/peptide 9 
nanoparticles are able to facilitate long-term restoration of the CFTR deficiency in CF mice. 
While zinc-finger nucleases and CRISPR/Cas9 systems have previously been evaluated for 
CF genome editing in vitro
173,174
, modification frequencies were low and delivery systems for 
in vivo translation were absent. Peptide-poloxamine nanoparticles in the present study could 
potentially be competent in vivo carriers for these genome editing tools. 
 
In addition, preliminary studies indicated that ternary complex strategy is also generalizable to 
other amphiphilic block copolymers, including poloxamine 304, 904 and 90R4 as well as 
poloxamer L64. Considering that poloxamine and poloxamer-based copolymers also mediate 
efficient in vivo gene transfer in skeletal muscle and myocardial tissues, and a poloxamer-
based delivery vehicle (poloxamer CRL1005) has progressed into clinical trials
75,203,204
, the 
modular design approach of synthetic peptide platform also allows the flexible exchange of 
targeting moieties showing high affinity to these tissues. As a result, the platform in current 
study holds great promising in the gene therapy of related diseases within these tissues. 
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5 ZUSAMMENFASSUNG 
 
Ich habe in meiner Dissertation die Grundlagen gelegt für die Etablierung einer 
Plattformtechnologie, die eine effiziente in vitro Transfektion von Nukleinsäuren mittels  
Poloxamin-basierter Blockcopolymere in Kombination mit synthetischen Peptiden 
ermöglicht. Die Peptidkomponente vermittelt in Anwesenheit von T704 und Nukleinsäuren 
die Ausbildung kompakter ternärer Komplexe über eine einfache Selbstorganisation und 
ermöglicht somit eine effiziente in vitro- und in vivo-Gen-Transfektion. Der Transfer von 
mRNA durch Peptid-T704-Nanopartikel führte zu einer 35-mal höheren Transgenexpression 
im Vergleich zu 25 kDa brPEI. Der Transfer von pDNA- durch Peptid-T704-Nanopartikel 
führte zu einer vergleichbar hohen Transgenexpression wie dies bei Lipofectamin2000 
gemessen werden konnte, allerdings war die Peptid-T704-Nanopartikel vermittelte 
Transfektion weniger zytotoxisch. In Transfektionsstudien bei CF-Mäusen wurde die 
Überlegenheit der Peptid-T704-Nanopartikel gegenüber den binären Komplexen und den 
lipidbasierten Formulierung  weiter validiert. 
 
Der ternäre Komplex enthält mehrere unterschiedliche Abschnitte, wodurch verschiedene 
extrazelluläre und intrazelluläre Barrieren überwunden werden können. T704 als wesentlicher 
Bestandteil der ternären Komplexe zeigt weniger unspezifische Wechselwirkungen mit 
extrazellulären Matrixkomponenten, wodurch biologische Barrieren besser überwunden 
werden können und das Epithel der Atemwege erreicht werden kann. Anschließend 
ermöglicht das synthetische Peptid im ternären Komplex die Bindung mit den Zielzellen, was 
dann zu  einer effizienten Abgabe der genetischen Nutzlast in die Zielzelle und Zielorganellen 
ermöglicht. Wichtig ist, dass der ternäre Komplex sowohl in vitro als auch in in vivo 
Anwendungen ein  geringes Nebenwirkungsprofil zeigte. Die biologische Abbaubarkeit von 
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synthetischen Peptiden ist ein zusätzlicher vorteilhafter Faktor, wenn wiederholte 
Applikationen erforderlich sind. Aufgrund dieser Vorteile ist der ternäre Komplex in der 
Lage, kultivierte Epithelzellen sowie Atemwegsepithelien von Mäusen effizient zu 
transfizieren, dies unterstreicht das große Anwendungspotential ternärer Komplexe für den 
pulmonalen Gentransfer. 
 
Obwohl die nichtvirale Applikation des Transposonsystems bisher als ineffizient in 
somatischen Zellen für die in vivo therapeutische Anwendung angesehen wurde
200
, konnte im 
Rahmen dieser Arbeit gezeigt werden, dass durch SB-Transposon/T704/Peptid 9 Nanopartikel 
eine langfristige Wiederherstellung einer CFTR--Expression bei CF-Mäusen  erreicht werden 
konnte. Für Zinkfinger-Nukleasen und CRISPR/Cas9-Systeme liegen erste Ergebnisse  für die 
CF-Genom-Modifikation  in vitro vor
173,174
; die Effizienz dieser Ansätze war niedrig und  in 
vivo Daten fehlen. Peptid-Poloxamin-Nanopartikel könnten potentiell effiziente in vivo Träger 
für das Verfahren des Genom-Editierens  sein. 
 
Darüber hinaus zeigten vorläufige Studien, dass die ternäre Komplexformulierungsstrategie 
auch für andere amphiphile Blockcopolymere, einschließlich Poloxamin 304, 904 und 90R4 
sowie Poloxamer L64, verwendbar ist. In Anbetracht der Tatsache, dass Poloxamin- und 
Poloxamer-basierte Copolymere auch einen effizienten in vivo Gentransfer im Skelettmuskel- 
und Myokardgewebe vermitteln und ein Poloxamer-basiertes Carrier-System (Poloxamer 
CRL1005) in klinischen Studien erprobt wird
75,203,204
, ermöglicht der modulare Designansatz 
der synthetischen Peptidplattform auch einen flexiblen Austausch von Targeting-Liganden 
mit hoher Affinität zu diesen Geweben. Zusammenfassend kann festgestellt werden, dass  die 
in dieser Dissertation entwickelte Plattformtechnologie ein vielversprechender Ansatz für  
eine Reihe von Gentransfer-Verfahren in unterschiedliche Gewebe und Zielzellen sein kann.
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6 APPENDIX 
6.1 Abbreviations 
16HBE: Human bronchial epithelial cell line 
7-AAD: 7-Aminoactinomycin D  
AAVs: Adeno-associated viruses 
ATP: Adenosine triphosphate 
BCs: Binary complexes formed by poloxamine 704 and nucleic acids 
BEAS-2B: Human bronchial epithelia cell line 
brPEI:  Branched polyethyleneimine 
cAMP: Cyclic adenosine monophosphate 
cDNA: Complementary DNA 
CF: Cystic fibrosis  
CFBE-delF: Cells contain the most common CF phenotype causing mutation (Phe508del) 
CFBE-WT: Cells express wild type CFTR  
CFTR:  Cystic fibrosis transmembrane conductance regulator  
Cl
-
: Chloride ion 
CLSM: Confocal laser scanning microscope  
CpG:  Cytosine-phosphate-guanine motifs 
CPPs: Cell penetrating peptides  
CRISPR/Cas9: Clustered regularly interspaced short palindromic repeats/Cas9 nuclease 
DAPI: 4,6-diamidino-2-phenylindole  
DIPEA: N,N-diisopropylethylamine  
DLS: Dynamic light scattering  
DOPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine  
DOTAP: 1,2-dioleoyl-3-trimethylammoniumpropane  
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EDMPC:Chol: p-ethyl-dimyristoylphosphatidyl choline cholesterol liposomes 
EDTA: Ethylenediaminetetraacetic acid 
EGFP: Enhanced green fluorescent protein  
ER: Endoplasmic reticulum  
FACS: Flow cytometry 
FBS: Fetal bovine serum  
FCS: Fetal bovine serum 
fLUC: Firefly luciferase  
Fluo-pDNA: Fluorescein labelled plasmid DNA  
GL67A: Cationic lipids based nonviral gene transfection formulation 
HCO3
-
: Bicarbonate ion  
HCTU: 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
H&E: Haematoxylin-Eosin staining 
HPLC: High performance liquid chromatography 
HS: Heparan sulfate  
HSPG: Heparan sulfate proteoglycans  
ICAM-1: Intercellular adhesion molecule-1  
IC50: Half maximal inhibitory concentration  
IgG: Immunoglobulin G 
IVIS:  In Vivo Imaging System 
IVT mRNA: In vitro transcribed messenger RNA  
kDa: Kilo Dalton 
L64: Poloxamer 184  
LC/MS: Liquid chromatography-mass spectroscopy 
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ligand S: Short peptide sequence displays close similarity to receptor binding proteins of 
rhinovirus (sequence: SERSMNF) 
ligand Y: Short peptide closely resembles part of a targeting protein expressed by the 
intracellular pathogen Legionella pneumophila (sequence: YGLPHKF) 
lipoplex: Complex formed by cationic lipids and nucleic acids 
MetLuc: Metridia luciferase  
mM: Millimolar 
mRNA: Messenger RNA  
MTT: 3-(4,5- Dimethyl-2-tetrazolyl)-2,5-diphenyl-2Htetrazolium bromide  
MW: Molecular weight 
NF-water: Nuclease-free water  
NLS: Nuclear localization signal  
N/P ratio: The ratio between nitrogen residues in peptide and nucleic acids phosphate groups 
PBS: Phosphate buffer saline 
PDI: polydispersity index  
pDNA: Plasmid DNA  
PEG: Polyethylenglycol 
PEO: Poly(ethylene oxide) 
pGM206-fLUC-CFTR/T2: Plasmid  containing a T2 SB transposon encoding both firefly 
luciferase and Cystic Fibrosis Transmembrane Conductance Regulator 
pH: Potentia Hydrogenii 
Phe508del: The most common CF phenotype causing mutation which origins from the 
deletion of three nucleotides inducing a deletion of phenylalanine within the protein 
PLGA: Poly (lactic-co-glycolic acid) 
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Poloxamers: Nonionic triblock copolymers composed of a central hydrophobic chain 
of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains 
of polyoxyethylene (poly(ethylene oxide))  
Poloxamines: A subgroup of the poloxamers and structurally composed of an ethylene 
diamine core whose amino groups are substituted with copolymers of variable length 
polyoxyethylene and polyoxypropylene blocks 
Polyplex: Complex formed by cationic polymer and nucleic acids 
PPO: Poly(propylene oxide)  
RLU: Relative light units  
RT: Room temperature 
SB: Sleeping Beauty based transposon system 
SB100X: Sleeping Beauty 100X transposase  
SD: Standard deviation 
SNIM mRNA: Stabilized, non-immunogenic messenger RNA  
siRNA: Short interfering RNA 
T304: poloxamine 304  
T704: poloxamine 704  
T904: poloxamine 904 
T90R4: poloxamine 90R4 
TAE:  Tris-acetate-EDTA buffer 
TCs: Ternary complexes formed by T704, peptide and nucleic acids 
TEM: Transmission electron microscopy  
TFA: Trifluoroacetic acid  
TLR: Toll-like receptor  
v/v: Volume percent 
wtCFTR: Wild type CFTR  
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w/v: Mass concentration 
w/w: Weight to weight ratio 
 
6.2 Supporting figures and tables 
 
Supplementary Table 1. Currently available poloxamine varieties commercialized by BASF under the trade 
name Tetronic
® obtained from BASF web page 
Tetronic Mw (Da) EO units 
per block 
PO units 
per block 
HLB Solubility* Cloud 
point** 
pKa 
304 1650 3.7 4.3 12-18 > 10 75 4.3; 8.1 
701 3600 2.1 14.0 1-7 Insoluble 18 4.0; 7.9 
901 4700 2.7 18.2 1-7 Insoluble 20 5.1; 7.6 
904 6700 15 17 12-18 > 10 74 4.0; 7.8 
908 25000 114 21 > 24 > 10 > 100 5.2; 7.9 
1107 15000 60 20 18-23 > 10 > 100 5.6; 7.9 
1301 6800 4 26 1-7 Insoluble 16 4.1; 6.2 
1304 10500 21.4 27.1 12-18 > 10 --- --- 
1307 18000 72 23 > 24 > 10 > 100 4.6; 7.8 
90R4 6900 16 18 1-7 > 10 43 --- 
150R1 8000 5 30 1-7 Insoluble 20 4.8; 7.5 
*represents solubility in water at 25℃ (w/w %)  
**represents cloud point of 1 % (℃)
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Supplementary Figure 1 In vitro transfection profile of Lipofectamine2000 based lipoplexes in cultured 
human bronchial epithelial cells (BEAS-2B and 16HBE). (a) 400 ng/well MetLuc-mRNA was complexed 
with Lipofectamine2000 at different concentrations from 0.2 to 1.0 µg/well (relative to 96-well plate) in 
OptiMEM. After 30 min incubation at room temperature (RT), samples were added into 96-well plate containing 
pre-seeded cells and incubated with cells in OptiMEM (without serum and antibiotics) for 4 h at 37 ℃ in a 
humidified atmosphere (95% air, 5% CO2). Luciferase activity in 50 µl supernatants from transfected cells was 
assayed after 24 h and its activity was expressed in RLU. (b) MetLuc-pDNA/Lipofectamine 2000 lipoplexes 
were prepared in the same way of mRNA counterpart, luciferase activity was measured 24 h, 48 h and 72 h after 
transfection and its activity was expressed in RLU. All experiments were performed at least three times. Data 
represent the mean ± SD (n>5). 
 
 
 
 
a 
b 
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Supplementary Figure 2 In vitro transfection profile of 25kDa brPEI based polyplexes in cultured human 
bronchial epithelial cells (BEAS-2B and 16HBE). (a) 400 ng/well MetLuc-mRNA was complexed with brPEI 
at different N/P ratios from 5 to 60 (relative to nucleic acids) in nuclease-free water. After 30 min incubation at 
RT, samples were added into 96-well plate containing pre-seeded cells and incubated with cells in OptiMEM 
(without serum and antibiotics) for 4 h at 37 ℃ in a humidified atmosphere (95% air, 5% CO2). Luciferase 
activity in 50 µl supernatants from transfected cells was assayed after 24 h and its activity was expressed in 
RLU. (b) MetLuc-pDNA/brPEI polyplexes were prepared in the same way of mRNA counterpart, luciferase 
activity was measured 24 h, 48 h and 72 h after transfection and its activity was expressed in RLU. All 
experiments were performed at least three times. The data are given as the mean ± SD (n>5). 
b 
a 
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Supplementary Figure 3 In vitro transfection profile of peptide 9 based binary complexes in BEAS-2B and 
16HBE cells. (a) 400 ng/well MetLuc-mRNA was complexed with peptide 9 at different N/P ratios from 2.5 to 
20 in NF-water. After 30 min incubation at RT, samples were added into 96-well plate containing pre-seeded 
cells and incubated with cells in Opti-MEM (without serum and antibiotics) for 4 h at 37 ℃ in a humidified 
atmosphere (95% air, 5% CO2). Luciferase activity in 50 µl supernatants from transfected in transfected BEAS-
2B or 16HBE cells was measured after 24 h and its activity was expressed in RLU. (b) MetLuc-pDNA/peptide 9 
binary complexes were prepared in the same way of mRNA counterpart, luciferase activity in 50 µl supernatants 
from transfected cells was measured 24 h, 48 h, 72h and 96 h after transfection and its activity was expressed in 
RLU. All experiments were performed at least three times. The data are given as the mean ± SD (n>5).  
a 
b 
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Supplementary Figure 4 Cellular uptake profiles of peptide 9 based ternary complex and Lipofectamine 
2000 based lipoplex. The uptake of (a) naked fluorescein labelled pDNA (Fluo-pDNA), (b) Fluo-
pDNA/T704/peptide 9 ternary complex and (c) Fluo-pDNA/Lipofectamine2000 lipoplex in 16HBE cells. 
a b 
c 
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Supplementary Figure 5 Binding and condensation properties of ternary complexes containing pDNA or 
mRNA. Complexes were incubated with increasing amounts of heparan sulfate (HS) per µg nucleic acid (NS). 
Naked nucleic acid was used as a positive control (+) and NF-water as a negative control (-). “DNA Lipoplex” 
represents Lipofectamine2000 based lipoplex containing pDNA in optimum composition. “mRNA Lipoplex” 
represents Lipofectamine2000 based lipoplex containing mRNA in optimum composition. 
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